<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Exp. Med</journal-id><journal-title-group><journal-title>The Journal of Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9874571</article-id><article-id pub-id-type="pmc">PMC1887697</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>An Essential Role for Nuclear Factor &#x003ba;B in Promoting Double Positive Thymocyte Apoptosis </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hettmann</surname><given-names>Thore</given-names></name><xref ref-type="aff" rid="N0x1a14700N0x3f82040">*</xref></contrib><contrib contrib-type="author"><name><surname>DiDonato</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="N0x1a14700N0x3f82040">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Karin</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="N0x1a14700N0x3f82040">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Leiden</surname><given-names>Jeffrey M.</given-names></name><xref ref-type="aff" rid="N0x1a14700N0x3f82040">*</xref></contrib></contrib-group><aff id="N0x1a14700N0x3f82040">From the <label>*</label>Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the <label>&#x02021;</label>Department of Pharmacology, University of California San Diego, San Diego, California 92093</aff><author-notes><fn><p>Address correspondence to Jeffrey M. Leiden, University of Chicago, Rm. B608 MC 6080, 5841 South Maryland Ave., Chicago, IL 60637. Phone: 773-702-1919; Fax: 773-702-1385; E-mail: <email>jleiden@medicine.bsd.uchicago.edu</email>
</p></fn></author-notes><pub-date pub-type="ppub"><day>4</day><month>1</month><year>1999</year></pub-date><volume>189</volume><issue>1</issue><fpage>145</fpage><lpage>158</lpage><history><date date-type="received"><day>6</day><month>7</month><year>1998</year></date><date date-type="rev-recd"><day>5</day><month>10</month><year>1998</year></date></history><permissions><copyright-year>1999</copyright-year><license license-type="openaccess"><license-p>This article is distributed under the terms of an Attribution&#x02013;Noncommercial&#x02013;Share Alike&#x02013;No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.rupress.org/terms">http://www.rupress.org/terms</ext-link>). After six months it is available under a Creative Commons License (Attribution&#x02013;Noncommercial&#x02013;Share Alike 4.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>).</license-p></license></permissions><abstract><p>To examine the role of nuclear factor (NF)-&#x003ba;B in T cell development and activation in vivo, we produced transgenic mice that express a superinhibitory mutant form of inhibitor &#x003ba;B-&#x003b1; (I&#x003ba;B-&#x003b1;<sub>A32/36</sub>) under the control of the T cell&#x02013;specific CD2 promoter and enhancer (mutant [m]I&#x003ba;B-&#x003b1; mice). Thymocyte development proceeded normally in the mI&#x003ba;B-&#x003b1; mice. However, the numbers of peripheral CD8<sup>+</sup> T cells were significantly reduced in these animals. The mI&#x003ba;B-&#x003b1; thymocytes displayed a marked proliferative defect and significant reductions in interleukin (IL)-2, IL-3, and granulocyte/macrophage colony-stimulating factor production after cross-linking of the T cell antigen receptor. Perhaps more unexpectedly, double positive (CD4<sup>+</sup>CD8<sup>+</sup>; DP) thymocytes from the mI&#x003ba;B-&#x003b1; mice were resistant to &#x003b1;-CD3&#x02013;mediated apoptosis in vivo. In contrast, they remained sensitive to apoptosis induced by &#x003b3;-irradiation. Apoptosis of wild-type DP thymocytes after in vivo administration of &#x003b1;-CD3 mAb was preceded by a significant reduction in the level of expression of the antiapoptotic gene, <italic>bcl-x<sub>L</sub></italic>. In contrast, the DP mI&#x003ba;B-&#x003b1; thymocytes maintained high level expression of <italic>bcl-x<sub>L</sub></italic> after &#x003b1;-CD3 treatment. Taken together, these results demonstrated important roles for NF-&#x003ba;B in both inducible cytokine expression and T cell proliferation after TCR engagement. In addition, NF-&#x003ba;B is required for the &#x003b1;-CD3&#x02013;mediated apoptosis of DP thymocytes through a pathway that involves the regulation of the antiapoptotic gene, <italic>bcl-x<sub>L</sub></italic>.</p></abstract><kwd-group><kwd>nuclear factor &#x003ba;B</kwd><kwd>inhibitor &#x003ba;B-&#x003b1;<sub>A32/36</sub></kwd><kwd>thymocytes</kwd><kwd>apoptosis</kwd><kwd><italic>bcl-x<sub>L</sub></italic></kwd></kwd-group></article-meta></front><body><p>The mammalian nuclear factor (NF)-&#x003ba;B<sup>1</sup> transcription factors, NF-&#x003ba;B1 (p50/p105), NF-&#x003ba;B2 (p52/p100), RelA (p65), c-Rel, and RelB are involved in the regulation of immune and inflammatory responses, cellular proliferation, and cell death (for review see references <xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>). NF-&#x003ba;B proteins modulate these diverse biological processes by regulating the expression of a wide variety of genes encoding cytokines and cytokine receptors, chemokines, cell adhesion molecules, cell-surface receptors, hematopoietic growth factors, acute phase proteins, and other transcription factors. Transcriptional activation or repression of NF-&#x003ba;B target genes requires binding of NF-&#x003ba;B dimers to &#x003ba;B DNA binding sites. Although p50/p65 heterodimers are considered the prototypical NF-&#x003ba;B dimer, many different combinations of NF-&#x003ba;B homo- and heterodimers exist (<xref rid="B5" ref-type="bibr">5</xref>) and there is evidence to suggest that these different NF-&#x003ba;B dimers regulate the expression of different genes (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>In most cells, the transcriptional activity of NF-&#x003ba;B proteins is controlled at the posttranslational level by regulated associations with members of the inhibitor (I)&#x003ba;B family of inhibitory proteins. NF-&#x003ba;B proteins are retained in the cytoplasm of unstimulated cells and thus rendered inactive via interactions with one or more of the seven known I&#x003ba;B proteins: I&#x003ba;B-&#x003b1;, I&#x003ba;B-&#x003b2;, I&#x003ba;B-&#x003b3;, Bcl-3, I&#x003ba;B-&#x003b5;, p105, and p100 (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B7" ref-type="bibr">7</xref>). In response to a wide variety of stimuli, including antigen receptor cross-linking, and exposure to cytokines (TNF-&#x003b1;, IL-1), bacterial components (LPS), viruses, ionizing radiation, or oxidative stress, I&#x003ba;B-&#x003b1; and -&#x003b2; proteins are phosphorylated and degraded and cytoplasmic NF-&#x003ba;B dimers released from their inhibitory proteins are rapidly translocated to the nucleus where they regulate the transcription of genes containing &#x003ba;B binding sites (<xref rid="B8" ref-type="bibr">8</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). Recent studies have demonstrated that phosphorylation of Ser<sub>32</sub> and Ser<sub>36</sub> and subsequent polyubiquitination of I&#x003ba;B-&#x003b1; are essential for the release and nuclear translocation of NF-&#x003ba;B dimers (<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). Substitution of I&#x003ba;B-&#x003b1; Ser<sub>32</sub> and Ser<sub>36</sub> by Ala residues prevents phosphorylation and degradation of I&#x003ba;B-&#x003b1;, thereby retaining NF-&#x003ba;B dimers in an inactive form in the cytoplasm.</p><p>NF-&#x003ba;B proteins are thought to play important roles in T cell activation and development (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Functionally important &#x003ba;B binding sites have been identified in a large number of T cell transcriptional regulatory elements, including the IL-2, IL-2R&#x003b1;, G-CSF, and macrophage inflammatory protein (MIP)-2 promoters (<xref rid="B1" ref-type="bibr">1</xref>). Preformed NF-&#x003ba;B proteins are present in the cytoplasm of thymocytes and resting peripheral T cells (<xref rid="B21" ref-type="bibr">21</xref>). TCR engagement results in the rapid phosphorylation of I&#x003ba;B-&#x003b1; and the concomitant nuclear migration of active NF-&#x003ba;B dimers (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Despite these findings, it has been difficult to precisely elucidate the role of NF-&#x003ba;B in regulating T cell development, activation, and apoptosis in vivo. During the last several years, gene targeting experiments have demonstrated that RelB, c-Rel, and NF-&#x003ba;B1 each play important but distinct roles in regulating the development and function of the mammalian immune system. NF-&#x003ba;B1&#x02013;deficient mice displayed defects in B cell proliferation in response to the mitogen LPS but not to IgM cross-linking (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). RelB is required for the differentiation and/or survival of dendritic cells and thymic medullary epithelial cells and RelB<sup>&#x02212;/&#x02212;</sup> mice displayed severely defective cellular immune responses (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). The immune dysfunction observed in RelB<sup>&#x02212;/&#x02212;</sup> mice was worsened in NF-&#x003ba;B1/RelB double knockout mice, suggesting that the lack of RelB is compensated for by other NF-&#x003ba;B1&#x02013;containing dimers (<xref rid="B28" ref-type="bibr">28</xref>). c-Rel&#x02013;deficient mice displayed defective B and T cell proliferation in response to mitogen stimulation as well as markedly decreased IL-2 production after TCR engagement (<xref rid="B29" ref-type="bibr">29</xref>). In contrast, mice lacking RelA died on embryonic day 15 from massive hepatocyte apoptosis (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). However, progenitor cells derived from RelA<sup>&#x02212;/&#x02212;</sup> mice were able to give rise to normal T cells, suggesting that RelA is not required for T cell development (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p><p>Recent studies have suggested that, in addition to regulating lymphocyte function, NF-&#x003ba;B proteins might play a critical role in protecting cells against apoptosis. Support for this model came both from the finding of hepatocyte apoptosis in the RelA<sup>&#x02212;/&#x02212;</sup> mice and from experiments demonstrating that overexpression of a dominant-negative form of the I&#x003ba;B-&#x003b1; protein in transgenic mice (<xref rid="B33" ref-type="bibr">33</xref>) and several cell lines promoted apoptosis in vitro (<xref rid="B34" ref-type="bibr">34</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>). However, other studies have suggested that NF-&#x003ba;B can also function in a proapoptotic fashion. For example, induction of apoptosis in 293 cells after serum withdrawal requires RelA activation (<xref rid="B40" ref-type="bibr">40</xref>). Similarly, radiation-induced apoptosis in ataxia telangiectasia cells is suppressed by dominant-negative I&#x003ba;B-&#x003b1; proteins (<xref rid="B41" ref-type="bibr">41</xref>) and inhibition of NF-&#x003ba;B activation prevents apoptosis in cultured human thymocytes (<xref rid="B42" ref-type="bibr">42</xref>). Finally, NF-&#x003ba;B activation promotes apoptosis in neural cells (<xref rid="B43" ref-type="bibr">43</xref>) and T cell hybridomas (<xref rid="B44" ref-type="bibr">44</xref>), and high levels of c-Rel induce apoptosis in avian embryos and in bone marrow cells in vitro (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>Although gene targeting experiments have been useful for identifying the essential nonredundant roles of individual NF-&#x003ba;B transcription factors in T cell development and function, the interpretation of these experiments can be obscured by functional redundancies of related gene products in the mutant animals and by embryonic lethal phenotypes that preclude a complete analysis of lymphoid development and function. Moreover, in some cases it can be difficult to distinguish cell autonomous and non&#x02013;cell autonomous phenotypes because mutant animals lack expression of the targeted gene in all cell lineages. We and others (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B46" ref-type="bibr">46</xref>) have used a complementary approach that circumvents these potential problems to study the role of NF-&#x003ba;B in T cell development, activation, and apoptosis in vivo. Specifically, we have generated transgenic mice that express a mutant superinhibitory form of the I&#x003ba;B-&#x003b1; protein under the control of the T cell&#x02013;specific CD2 promoter and enhancer. This superinhibitory form of I&#x003ba;B-&#x003b1; cannot be phosphorylated on Ser<sub>32</sub> and Ser<sub>36</sub> and degraded in response to TCR cross-linking and would therefore be expected to constitutively inhibit the nuclear translocation of NF-&#x003ba;B proteins after T cell activation. Studies of the mI&#x003ba;B-&#x003b1; mice revealed several important functions for NF-&#x003ba;B in T cells in vivo. First, NF-&#x003ba;B is required to develop or maintain normal numbers of peripheral CD8<sup>+</sup> T cells. Second, NF-&#x003ba;B activation is necessary for both cytokine production and thymocyte proliferation after TCR engagement. Finally and somewhat unexpectedly, NF-&#x003ba;B is required for &#x003b1;-CD3&#x02013;mediated apoptosis of double positive (DP) thymocytes in vivo via a pathway that involves downregulated expression of the antiapoptotic gene <italic>bcl-x<sub>L</sub></italic> in DP thymocytes.</p><sec sec-type="materials|methods" id="MaterialsMethods"><title>Materials and Methods</title><sec disp-level="3"><title>Transgene Construction and Generation of Transgenic Mice.</title><p> The construction of the hemagglutinin (HA)-tagged I&#x003ba;B-&#x003b1; cDNA with Ser to Ala substitutions at positions 32 and 36 has been described previously (<xref rid="B47" ref-type="bibr">47</xref>). The mutant I&#x003ba;B-&#x003b1; cDNA was inserted into the XhoI site of pTEx (provided by Dr. M. Owen, Imperial Cancer Research Fund, London, UK), which contains the promoter, polyadenylation site, and locus control region elements from the human CD2 gene (<xref rid="B48" ref-type="bibr">48</xref>). Transgene DNA was microinjected into the male pronucleus of fertilized single cell embryos of CD1 mice. Microinjected eggs were transferred to pseudopregnant CD1 foster mothers. EcoRI-digested tail DNA from 12&#x02013;14-d-old pups was hybridized to a radiolabeled 0.8-kb I&#x003ba;B-&#x003b1;&#x02013;specific probe, and the transgene copy number was determined using a PhosphorImager (Molecular Dynamics).</p></sec><sec disp-level="3"><title>Cell Culture.</title><p>Single cell suspensions of thymocytes and splenocytes were cultured at 37&#x000b0;C, 5% CO<sub>2</sub> in RPMI 1640 medium containing 10% heat inactivated FCS, 100 U/ml penicillin/streptomycin, 2 mM glutamine, 0.1 mM nonessential amino acids, 5.5 &#x000d7; 10<sup>2</sup> &#x003bc;M &#x003b2;-ME (all from <named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>). Thymocyte proliferation assays were performed in 96-well plates (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content>) that had been coated overnight with &#x003b1;-CD3 mAb (145-2C11; <named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>) and/or &#x003b1;-CD28 mAb (37.51; <named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>) at a concentration of 16 &#x003bc;g/ml. Stimulation with PMA (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>) and ionomycin (<named-content content-type="company" xlink:href="calbio">Calbiochem</named-content>) was performed at 5 ng/ml and 0.25 &#x003bc;g/ml, respectively. After stimulation for 48 h, cells (0.5 &#x000d7; 10<sup>6</sup>/ml) were pulsed for 18 h at 37&#x000b0;C with [<sup>3</sup>H]thymidine (1 &#x003bc;Ci/ml; <named-content content-type="company" xlink:href="amersham">Amersham</named-content>). Cells were transferred onto glass fiber filter mats and radioactive incorporation was measured with a beta scintillation counter.</p></sec><sec disp-level="3"><title>Fetal Thymic Organ Culture.</title><p>Fetuses of CD1 and mI&#x003ba;B-&#x003b1; mice were obtained at embryonic day 17.5 of pregnancy, counting the day of vaginal plug as embryonic day 1. Equally sized thymic lobes were cultured in 24-well Transwell dishes (Costar Corp.) containing complete DMEM-10 medium. The samples were maintained in an atmosphere of 5% CO<sub>2</sub> for 72 h and treated with &#x003b1;-CD3 mAb (145-2C11) as described in the text.</p></sec><sec disp-level="3"><title>ELISA Assays.</title><p>For ELISA assays, 96-well plates (Dynatech Labs.) were coated overnight at 4&#x000b0;C with &#x003b1;&#x02013;IL-2 (JES6-1A12), &#x003b1;&#x02013;IL-3 (MP2-8F8), or &#x003b1;&#x02013;GM-CSF (MP1-22E9) mAbs (<named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>). Serial dilutions of supernatants from thymocytes stimulated in culture for 48 h were added to the antibody-coated plates and incubated for 18 h at 4&#x000b0;C. Biotinylated antibodies against IL-2 (JES5-5H4), IL-3 (MP2-43D11), or GM-CSF (MP1-31G6) were then added to the plates and incubated for 2 h at room temperature. Avidin peroxidase (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>) and ABTS (3-ethylbenzthiazoline-6-sulfonic acid) were added to the wells and enzymatic reactions were quantitated in a microplate reader (Dynatech Labs.). All samples were assayed in triplicate.</p></sec><sec disp-level="3"><title>Western Blot Analysis.</title><p>Cytoplasmic and nuclear thymocyte extracts were prepared as previously described (<xref rid="B49" ref-type="bibr">49</xref>). In brief, thymocytes were washed with PBS, incubated in buffer A (10 mM Hepes, pH 7.9, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0.5 mM dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride) for 10 min at 4&#x000b0;C and centrifuged to separate nuclei (pellet) from cytoplasmic proteins (supernatant). Nuclei were lysed by incubation with buffer C (20 mM Hepes, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 10 mg/ml leupeptin) at 4&#x000b0;C and lysates were cleared by centrifugation. Nuclear and cytoplasmic extracts were frozen at &#x02212;70&#x000b0;C. Protein concentrations were determined using a commercially available kit (Bio-Rad). For Western blot analysis, 15 &#x003bc;g of cytoplasmic extracts were fractionated by SDS-PAGE in 10% polyacrylamide gels and transferred to PVDF membranes (<named-content content-type="company" xlink:href="millipore">Millipore</named-content>). Western blots were probed with a rabbit polyclonal antibody against MAD-3 (1:2,000 dilution; nomenclature of DiDonato et al. [reference <xref rid="B13" ref-type="bibr">13</xref>], No. 644) or an &#x003b1;-HA-specific antibody (1:2,000 dilution; 12CA5). Blots were developed with goat &#x003b1;-rabbit (1:2,000 dilution; <named-content content-type="company" xlink:href="amersham">Amersham</named-content>) or rat &#x003b1;-mouse (1:5,000 dilution; Kirkegaard and Perry Labs.) secondary antibodies and a commercially available chemiluminescence kit according to the manufacturer's instructions (<named-content content-type="company" xlink:href="pierce">Pierce Chemical Co.</named-content>).</p></sec><sec disp-level="3"><title>Electrophoretic Mobility Shift Assay.</title><p>A double-stranded oligonucleotide, spanning the &#x003ba;B site of the IL-2R&#x003b1; promoter (<xref rid="B50" ref-type="bibr">50</xref>) (5&#x02032; GGAACGGCAGGGGAATTCCCCTCTCCTT 3&#x02032;) was labeled with <sup>32</sup>P-nucleotides using the Klenow fragment of DNA polymerase I. Binding reactions contained 2 &#x003bc;g nuclear extract, 20,000 disintegrations per min (0.1&#x02013;0.5 ng) of radiolabeled oligonucleotide probe, 2 &#x003bc;g poly (dI-dC) in 75 mM KCl, 10 mM Tris, pH 7.5, 1 mM dithiothreitol, 1 mM EDTA, and 4% (vol/ vol) Ficoll in a final volume of 20 &#x003bc;l. After incubation on ice for 30 min, DNA protein complexes were fractionated by electrophoresis in nondenaturing 4% polyacrylamide gels at 120 V for 2.5 h in running buffer (25 mM Tris, 25 mM Boric acid, and 0.5 mM EDTA) with 47 &#x003bc;M &#x003b2;-ME. For competition experiments, 50 ng of unlabeled NF-&#x003ba;B oligonucleotide was added to the binding reaction before addition of the radiolabeled oligonucleotide probe. For antibody supershift experiments, the nuclear extracts were incubated with 1 &#x003bc;l of &#x003b1;-p50 (F056), &#x003b1;-RelB (A277), &#x003b1;-p65 (B127), or &#x003b1;-c-Rel (L036) antibodies (all from <named-content content-type="company" xlink:href="sbct">Santa Cruz Biotechnology</named-content>) before starting the binding reactions.</p></sec><sec disp-level="3"><title>Flow Cytometry.</title><p>Single cell suspensions of lymphocytes (10<sup>6</sup> cells) were washed in PBS and incubated with PE&#x02013;&#x003b1;-CD4 (RM4-5), FITC&#x02013;&#x003b1;-CD8 (53-6.7), FITC&#x02013;&#x003b1;-CD3 (145-2C11), and/or PE&#x02013;&#x003b1;-TCR-&#x003b1;/&#x003b2; (H57-97) mAbs (<named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>) in PBS plus 0.1% BSA for 30 min on ice. After staining, the cells were washed in PBS and analyzed on a FACScan<sup>&#x000ae;</sup> (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content>). Each plot represents analysis of &#x0003e;10<sup>4</sup> events using WinMDI software (Windows Multiple Document Interface, version 2.5). For intracellular staining, 10<sup>6</sup> thymocytes were stained with Cy-Chrome&#x02013; &#x003b1;-CD4 (RM4-5) and PE&#x02013;&#x003b1;-CD8 (53-6.7), and fixed in 4% paraformaldehyde. Fixed thymocytes were washed with 0.03% saponin (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>) and incubated with 100 &#x003bc;l 0.3% saponin, 20 &#x003bc;l blocking serum (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>) and FITC&#x02013; &#x003b1;-Bcl-x<sub>L</sub> (7B2.5) (Southern Biotechnology Associates). After 30 min of incubation at 4&#x000b0;C, cells were washed twice in 0.03% saponin followed by one wash in FACS buffer before FACScan<sup>&#x000ae;</sup> analysis.</p></sec><sec disp-level="3"><title>Ribonuclease Protection Assays.</title><p>Ribonuclease protection assays were performed using a commercially available kit as described by the manufacturer (<named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>) using the mAPO-2 multiprobe template set, 10 &#x003bc;g thymic RNA, and 0.1 mCi &#x003b1;-[<sup>32</sup>P]UTP (<named-content content-type="company" xlink:href="amersham">Amersham</named-content>). RNAse&#x02013;protected fragments were resolved by electrophoresis in polyacrylamide gels and visualized by autoradiography (<named-content content-type="company" xlink:href="kodak">Eastman Kodak Co.</named-content>).</p></sec><sec disp-level="3"><title>TUNEL Assays.</title><p>TUNEL (Tdt-mediated dUTP nick end labeling) assays were performed on paraffin-embedded sections of thymi according to Gavrieli et al. (<xref rid="B51" ref-type="bibr">51</xref>). Photomicrographs were obtained with a <named-content content-type="company" xlink:href="zeiss">Zeiss</named-content> Axioskop.</p></sec></sec><sec id="Results"><title>Results</title><sec disp-level="4"><title>Production of mI&#x003ba;B-&#x003b1; Transgenic Mice.</title><p>To inhibit inducible NF-&#x003ba;B activity in thymocytes in vivo, we produced transgenic mice that expressed a &#x0201c;superinhibitory&#x0201d; form of I&#x003ba;B-&#x003b1; under the control of the T cell&#x02013;specific CD2 promoter and enhancer (mI&#x003ba;B-&#x003b1; mice). We chose to use an I&#x003ba;B-&#x003b1; transgene because previous studies have demonstrated that I&#x003ba;B-&#x003b1; plays a critical role in regulating inducible NF-&#x003ba;B expression (for review see references <xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B52" ref-type="bibr">52</xref>). The superinhibitory mI&#x003ba;B-&#x003b1;<sub>A32/36 </sub>transgene containing Ser<sub>32</sub> and Ser<sub>36</sub> to Ala substitutions cannot be phosphorylated and degraded in response to TCR engagement and would therefore be expected to constituitively inhibit NF-&#x003ba;B activity in both resting and activated thymocytes and T cells. The CD2 promoter and enhancer (48, 53; Fig. <xref ref-type="fig" rid="F1">1</xref> A) were used in these studies because (a) they program T cell&#x02013; specific transgene expression and (b) they are expressed at high levels in all thymocyte subsets including double negative (CD4<sup>&#x02212;</sup>CD8<sup>&#x02212;</sup>; DN), DP (CD4<sup>+</sup>CD8<sup>+</sup>), and single positive (CD4<sup>+</sup> or CD8<sup>+</sup>; SP) cells (<xref rid="B54" ref-type="bibr">54</xref>). The transgene construct also contained three copies of an 11-amino acid influenza virus HA epitope tag (<xref rid="B55" ref-type="bibr">55</xref>) that allowed us to distinguish the transgene-encoded protein from endogenous murine I&#x003ba;B-&#x003b1;. A line of mI&#x003ba;B-&#x003b1; mice containing &#x0223c;12 copies of the transgene was produced by injection of this construct into fertilized CD1 mouse embryos (Fig. <xref ref-type="fig" rid="F1">1</xref> B). Homozygous transgenic mice were generated by breeding heterozygous littermates in order to obtain maximal levels of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> protein expression, an important consideration in producing a dominant-negative phenotype. A second line of transgenic mice expressing the I&#x003ba;B-&#x003b1;<sub>A32/36</sub> cDNA under the control of the proximal <italic>lck</italic> promoter and the CD2 enhancer was also produced (data not shown). Similar phenotypes were observed in both lines of transgenic mice and are therefore not distinguished in the results described below. </p><p>Endogenous I&#x003ba;B-&#x003b1; is phosphorylated and degraded after treatment of T cells with the NF-&#x003ba;B inducer, TNF-&#x003b1; (<xref rid="B47" ref-type="bibr">47</xref>). To analyze the relative levels of endogenous and transgene-encoded I&#x003ba;B-&#x003b1; and to study the differential regulation of the two proteins in response to TNF-&#x003b1;, we performed Western blot analyses using whole cell extracts from mI&#x003ba;B-&#x003b1; and control thymocytes that had been treated for different times with TNF-&#x003b1; (Fig. <xref ref-type="fig" rid="F2">2</xref> A). Basal levels of the I&#x003ba;B-&#x003b1;<sub>A32/36</sub> protein as detected with both the &#x003b1;-HA and &#x003b1;-I&#x003ba;B-&#x003b1; (&#x003b1;-MAD) antibodies slightly exceeded levels of the endogenous I&#x003ba;B-&#x003b1; protein in the mI&#x003ba;B-&#x003b1; thymocytes. In both wild-type and mI&#x003ba;B-&#x003b1; thymocytes, endogenous I&#x003ba;B-&#x003b1; was almost completely degraded after 15 min of TNF-&#x003b1; treatment and remained undetectable until &#x0223c;30 min after treatment. As previously reported (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B15" ref-type="bibr">15</xref>), endogenous I&#x003ba;B-&#x003b1; was reexpressed between 30 and 60 min after TNF-&#x003b1; treatment (data not shown). This reexpression reflects NF-&#x003ba;B&#x02013;mediated activation of the I&#x003ba;B-&#x003b1; promoter. In marked contrast, levels of the transgene-encoded I&#x003ba;B-&#x003b1;<sub>A32/36</sub> were unchanged by TNF-&#x003b1; treatment at all time points (Fig. <xref ref-type="fig" rid="F2">2</xref> A). Activation of mI&#x003ba;B-&#x003b1; thymocytes with PMA plus ionomycin or TCR cross-linking resulted in a similar degradation of endogenous I&#x003ba;B-&#x003b1;, whereas the levels of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> remain unaffected (data not shown). </p><p>To analyze the effects of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> expression on the nuclear translocation of NF-&#x003ba;B proteins after T cell activation, we performed electrophoretic mobility shift assays (EMSAs) using nuclear extracts prepared from both resting thymocytes and thymocytes activated in vivo by intraperitoneal injection of an &#x003b1;-CD3 mAb (Fig. <xref ref-type="fig" rid="F2">2</xref> B). As reported previously, nuclear extracts from unstimulated wild-type and mI&#x003ba;B-&#x003b1; thymocytes both contained p50 homodimers that bound to the radiolabeled &#x003ba;B probe (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B56" ref-type="bibr">56</xref>). The presence of such p50 homodimers in uninduced thymic nuclear extracts probably reflected the fact that p50 binds to I&#x003ba;B proteins with lower affinity and therefore is not quantitatively retained in the cytoplasm of either wild-type or mI&#x003ba;B-&#x003b1; thymocytes (<xref rid="B57" ref-type="bibr">57</xref>). Because p50 homodimers do not contain a transcriptional activation domain they are thought to repress &#x003ba;B-dependent gene expression (<xref rid="B58" ref-type="bibr">58</xref>). After activation with &#x003b1;-CD3 mAb, the level of p50 homodimers increased equivalently in the wild-type and mI&#x003ba;B-&#x003b1; thymocyte nuclear extracts. In addition, an inducible low mobility &#x003ba;B binding complex appeared in the nuclear extracts of wild-type thymocytes. Antibody supershift experiments demonstrated that this complex contained predominantly p50/p65 heterodimers as well as smaller amounts of c-Rel&#x02013; and RelB-containing heterodimers (Fig. <xref ref-type="fig" rid="F2">2</xref> B). The induction of this low mobility &#x003ba;B binding activity was markedly inhibited after &#x003b1;-CD3&#x02013;mediated activation of the mI&#x003ba;B-&#x003b1; thymocytes (Fig. <xref ref-type="fig" rid="F2">2</xref> B). Taken together, these Western blotting and EMSA experiments demonstrated that thymocytes from the mI&#x003ba;B-&#x003b1; transgenic animals expressed high levels of cytoplasmic I&#x003ba;B-&#x003b1;<sub>A32/36 </sub>protein that was not degraded after TCR engagement in vivo. Moreover, constitutive expression of the I&#x003ba;B-&#x003b1;<sub>A32/36</sub> protein significantly reduced the induction of nuclear p50/ p65, c-Rel/p50, and RelB/p50 NF-&#x003ba;B heterodimers after either TNF-&#x003b1; or &#x003b1;-CD3&#x02013;mediated activation of the mI&#x003ba;B-&#x003b1; thymocytes.</p></sec><sec disp-level="4"><title>Normal Thymocyte Ontogeny in the mI&#x003ba;B-&#x003b1; Transgenic Mice.</title><p>To investigate T cell development in the mI&#x003ba;B-&#x003b1; mice, thymocytes and peripheral T cells from transgenic and wild-type animals were analyzed by flow cytometry using antibodies specific for a variety of developmentally regulated T cell surface antigens (Fig. <xref ref-type="fig" rid="F3">3</xref>). Thymi from the mI&#x003ba;B-&#x003b1; animals contained normal populations of DN, DP, and SP cells. Levels of CD3 and TCR-&#x003b1;/&#x003b2; expression were also indistinguishable on wild-type and mI&#x003ba;B-&#x003b1; thymocytes (Fig. <xref ref-type="fig" rid="F3">3</xref> B), as were expression of TCR-&#x003b3;/&#x003b4; and heat-shock antigen (data not shown). Thus, expression of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> did not appear to perturb thymocyte ontogeny. Total numbers of SP peripheral T cells in both the spleen and the lymph nodes were normal in mI&#x003ba;B-&#x003b1; mice as were the numbers of splenic CD4<sup>+</sup> T cells. However, as described previously by Boothby at al. and Esslinger et al. (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B46" ref-type="bibr">46</xref>), the numbers of peripheral CD8<sup>+</sup> T cells were reduced by &#x0223c;50% in mI&#x003ba;B-&#x003b1; mice (Fig. <xref ref-type="fig" rid="F3">3</xref> C). </p></sec><sec disp-level="4"><title>Impaired Proliferation and Cytokine Production by mI&#x003ba;B-&#x003b1; Transgenic Thymocytes.</title><p>To assess the effects of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> expression on cytokine production and proliferation, thymocytes from mI&#x003ba;B-&#x003b1; and wild-type control littermates were activated in vitro for 72 h with PMA plus ionomycin, &#x003b1;-CD3 mAb, or &#x003b1;-CD3 plus &#x003b1;-CD28 mAbs. When compared with wild-type thymocytes, proliferation of the mI&#x003ba;B-&#x003b1; thymocytes was reduced by 63% in response to PMA plus ionomycin and by 78% after activation with &#x003b1;-CD3 mAb (Fig. <xref ref-type="fig" rid="F4">4</xref>). Previous studies have suggested that CD28 costimulation may function, at least in part, through an NF-&#x003ba;B&#x02013;dependent pathway (<xref rid="B59" ref-type="bibr">59</xref>). Therefore, we tested the ability of CD28 costimulation to rescue the defect in &#x003b1;-CD3&#x02013;mediated thymocyte proliferation seen in the mI&#x003ba;B-&#x003b1; thymocytes. Interestingly, the observed reductions in thymocyte proliferation were partially, but not completely, rescued by &#x003b1;-CD28 costimulation (Fig. <xref ref-type="fig" rid="F4">4</xref>). Thus, the CD28 signaling pathway can at least partially bypass the requirement for NF-&#x003ba;B activation in thymocyte activation by TCR engagement. </p><p>Many cytokine genes including IL-2, IL-3, and GM-CSF are potential targets for NF-&#x003ba;B (<xref rid="B60" ref-type="bibr">60</xref>). However, the role of NF-&#x003ba;B in regulating activation-specific cytokine expression in vivo, particularly the expression of the IL-2 gene, remains controversial. Therefore, we compared cytokine production by the wild-type and mI&#x003ba;B-&#x003b1; thymocytes after activation with &#x003b1;-CD3 plus &#x003b1;-CD28 mAbs (Fig. <xref ref-type="fig" rid="F5">5</xref>). As compared with wild-type thymocytes, the mI&#x003ba;B-&#x003b1; thymocytes displayed significantly decreased production of IL-2, IL-3, and GM-CSF after &#x003b1;-CD3 plus &#x003b1;-CD28 activation (Fig. <xref ref-type="fig" rid="F5">5</xref>). IL-2 production was most significantly reduced (28% of wild-type levels), whereas GM-CSF and IL-3 production were less dramatically inhibited (Fig. <xref ref-type="fig" rid="F5">5</xref>). Taken together, these experiments demonstrated that NF-&#x003ba;B is required both for the induction of multiple cytokines and for normal thymocyte proliferation after TCR cross-linking. </p></sec><sec disp-level="4"><title>DP I&#x003ba;B-&#x003b1;<sub>A32/36</sub> Thymocytes Are Protected against &#x003b1;-CD3&#x02013; mediated Apoptosis In Vivo.</title><p>Systemic administration of &#x003b1;-CD3 mAb has been shown to result in the rapid depletion of &#x0003e;90% of DP thymocytes by apoptosis (<xref rid="B61" ref-type="bibr">61</xref>). NF-&#x003ba;B positively regulates the expression of death-rescuing genes, thereby preventing TNF-&#x003b1;&#x02013;induced apoptosis at least in certain cell types (<xref rid="B34" ref-type="bibr">34</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>). Based upon these findings, it was reasonable to hypothesize that DP thymocytes from the mI&#x003ba;B-&#x003b1; mice that failed to activate NF-&#x003ba;B normally would display increased apoptosis after systemic administration of &#x003b1;-CD3 mAb. To directly test the role of NF-&#x003ba;B in mediating the &#x003b1;-CD3&#x02013;mediated apoptotic death of DP thymocytes, mI&#x003ba;B-&#x003b1; and wild-type animals were injected intraperitoneally with &#x003b1;-CD3 mAb and thymocyte subsets were assessed by flow cytometry 48 h after injection. As shown in Fig. <xref ref-type="fig" rid="F6">6</xref> and consistent with previous reports (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), treatment of wild-type animals with &#x003b1;-CD3 mAb resulted in dose-dependent reductions in the size of the DP thymocyte population. Wild-type animals treated with 40 &#x003bc;g of &#x003b1;-CD3 mAb displayed a 98% reduction in DP thymocytes within 48 h after &#x003b1;-CD3 administration. Somewhat surprisingly, this &#x003b1;-CD3&#x02013;mediated loss of DP thymocytes was completely and reproducibly prevented in the mI&#x003ba;B-&#x003b1; mice even after administration of 40 &#x003bc;g of &#x003b1;-CD3 mAb (Fig. <xref ref-type="fig" rid="F6">6</xref>). Similar reductions in DP thymocyte apoptosis were observed at both 24 and 48 h after injection and after administration of either 20 or 40 &#x003bc;g of &#x003b1;-CD3 mAb (Fig. <xref ref-type="fig" rid="F6">6</xref> and data not shown). </p><p>To confirm the protective effects of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> expression on DP thymocyte apoptosis in vivo, we performed TUNEL assays on thymi from wild-type and mI&#x003ba;B-&#x003b1; mice after intraperitoneal injection of &#x003b1;-CD3 mAb (Fig. <xref ref-type="fig" rid="F7">7</xref>). Large numbers of apoptotic cells were seen in wild-type thymi after treatment with &#x003b1;-CD3 mAb as compared with littermates treated with an isotype-matched control antibody. In contrast, the frequency of apoptotic cells in the mI&#x003ba;B-&#x003b1; thymi was dramatically reduced as compared with that observed in wild-type thymi after treatment with similar amounts of &#x003b1;-CD3 mAb (Fig. <xref ref-type="fig" rid="F7">7</xref>). </p></sec><sec disp-level="4"><title>DP I&#x003ba;B-&#x003b1;<sub>A32/36</sub> Thymocytes Remain Sensitive to &#x003b3; Irradiation&#x02013;induced Apoptosis In Vivo.</title><p>Like &#x003b1;-CD3 treatment, &#x003b3; irradiation of the thymus is known to cause DP thymocyte apoptosis in vivo (<xref rid="B64" ref-type="bibr">64</xref>). However, recent studies have suggested that these different apoptotic stimuli may use distinct signaling pathways to regulate programmed cell death. Given the resistance of mI&#x003ba;B-&#x003b1; DP thymocytes to &#x003b1;-CD3&#x02013;mediated apoptosis, it was of interest to determine the sensitivity of these cells to &#x003b3; irradiation in vivo. As shown in Fig. <xref ref-type="fig" rid="F6">6</xref> C, DP thymocytes from the mI&#x003ba;B-&#x003b1; mice remained fully sensitive to &#x003b3; irradiation&#x02013;induced apoptosis in vivo. Thus, expression of the I&#x003ba;B-&#x003b1;<sub>A32/36</sub> transgene protected DP thymocytes from apoptosis in response to &#x003b1;-CD3 but failed to protect these cells against &#x003b3; irradiation&#x02013; induced cell death.</p></sec><sec disp-level="4"><title>DP mI&#x003ba;B-&#x003b1; Thymocytes Are Resistant to &#x003b1;-CD3&#x02013;mediated Apoptosis in Fetal Thymic Organ Culture.</title><p>The administration of &#x003b1;-CD3 mAbs to mice in vivo can effect thymocytes either directly or indirectly via the activation of peripheral blood CD3<sup>+</sup> T cells. To attempt to distinguish these possibilities, we tested the susceptibility of mI&#x003ba;B-&#x003b1; thymocytes to &#x003b1;-CD3&#x02013; mediated apoptosis in fetal thymic organ culture (FTOC) (Fig. <xref ref-type="fig" rid="F8">8</xref>). Wild-type thymocytes were killed efficiently by 3 d of FTOC treatment with an &#x003b1;-CD3 mAb. In contrast, DP thymocytes from the mI&#x003ba;B-&#x003b1; mice were relatively resistant to &#x003b1;-CD3&#x02013;mediated killing in FTOC. These results suggested that at least some of the resistance to &#x003b1;-CD3&#x02013;mediated DP thymocyte apoptosis seen in the mI&#x003ba;B-&#x003b1; mice reflects a thymus-specific effect of transgene expression. </p></sec><sec disp-level="4"><title>DP mI&#x003ba;B-&#x003b1; Thymocytes Fail To Downregulate Bcl-x<sub>L</sub> after &#x003b1;-CD3 Treatment In Vivo</title><p>The Bcl-2 family of proteins is comprised of multiple members that function either as death agonists (Bax, Bak, Bcl-X<sub>S</sub>, and Bad) or death antagonists (Bcl-2, Bcl-x<sub>L</sub>, Bcl-x&#x003b3;, Mcl-1, A1, and Bcl-w) (<xref rid="B65" ref-type="bibr">65</xref>). Two antiapoptotic members of this family, Bcl-x<sub>L</sub> and Bcl-2, are expressed in a reciprocal pattern during thymocyte development. Bcl-2 is expressed at high levels in immature DN thymocytes. Its expression is downregulated in DP cells and it is then reexpressed as these DP cells mature to SP thymocytes and peripheral T cells (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). Conversely, Bcl-x<sub>L</sub> is expressed at low or undetectable levels in immature DN cells. Its expression is significantly upregulated in DP thymocytes, and it is then downregulated as these cells progress to the SP stage of thymocyte ontogeny (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Interestingly, DP thymocytes from transgenic mice that overexpress Bcl-2 or Bcl-x<sub>L</sub> are protected from multiple proapoptotic stimuli, including &#x003b1;-CD3 treatment in vivo (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>). Given these findings, it was logical to postulate that altered expression of Bcl-2-family genes in the mI&#x003ba;B-&#x003b1; thymocytes might account for their decreased susceptibility to proapoptotic stimuli. Accordingly, we used an RNAse protection assay to directly monitor the expression of Bcl-2&#x02013;related genes in thymocytes from wild-type and mI&#x003ba;B-&#x003b1; transgenic mice. As shown in Fig. <xref ref-type="fig" rid="F9">9</xref> A, both basal and &#x003b1;-CD3&#x02013;treated levels of <italic>bfl-1</italic>, <italic>bak</italic>, <italic>bax</italic>, <italic>bcl-2</italic>, and <italic>bad</italic> mRNAs were equivalent in wild-type and mI&#x003ba;B-&#x003b1; thymocytes. Similarly, we failed to detect differential expression of mRNAs encoding Fas, Fas-L, TRAF, TRADD, Fadd, RIP, and FLICE in either unstimulated or &#x003b1;-CD3&#x02013;treated wild-type and mI&#x003ba;B-&#x003b1; thymocytes (data not shown). Basal levels of <italic>bcl-x<sub>L</sub></italic> were equivalent in wild-type and mI&#x003ba;B-&#x003b1; thymocytes. However, after &#x003b1;-CD3 treatment, the expression of <italic>bcl-x<sub>L</sub></italic> was significantly decreased in the wild-type cells but was maintained at pretreatment levels in the mI&#x003ba;B-&#x003b1; thymocytes (Fig. <xref ref-type="fig" rid="F9">9</xref> A). </p><p>Because Bcl-x<sub>L</sub> is the predominant antiapoptotic protein expressed in DP thymocytes, the preferential loss of Bcl-x<sub>L</sub> from wild-type thymocytes after &#x003b1;-CD3 administration might have simply reflected the death of these DP cells. To confirm that the pattern of Bcl-x<sub>L</sub> protein expression paralleled that of the mRNA and to assess the possibility that the observed changes in <italic>bcl-x<sub>L</sub></italic> mRNA expression reflected the preferential death of the DP thymocytes in the wild-type animals, we performed Western blot analyses on thymocyte extracts 18 and 39 h after &#x003b1;-CD3 treatment in vivo. As shown in Fig. <xref ref-type="fig" rid="F9">9</xref> B, levels of Bcl-x<sub>L</sub> protein were significantly reduced in wild-type thymocytes at both 18 and 39 h after administration of &#x003b1;-CD3 mAb. In contrast, levels of Bcl-x<sub>L</sub> protein were maintained at unstimulated levels in the mI&#x003ba;B-&#x003b1; thymocytes at both time points. Because there is not a significant loss of DP thymocytes 18 h after &#x003b1;-CD3 treatment, these results indicated that the loss of Bcl-x<sub>L</sub> protein precedes thymocyte apoptosis and is prevented in the mI&#x003ba;B-&#x003b1; DP thymocytes. We confirmed this result by performing intracellular staining of viable DP thymocytes using Bcl-x<sub>L</sub>&#x02013;specific antibodies (Fig. <xref ref-type="fig" rid="F9">9</xref> C). 24 h after &#x003b1;-CD3 administration, viable DP thymocytes displayed a significant decrease in intracellular Bcl-x<sub>L</sub> as measured by flow cytometry. In contrast, DP thymocytes from the mI&#x003ba;B-&#x003b1; mice failed to downregulate intracellular Bcl-x<sub>L</sub> expression. In control experiments, SP CD4<sup>+</sup> thymocytes from these same wild-type and mI&#x003ba;B-&#x003b1; animals both failed to demonstrate altered levels of intracellular Bcl-x<sub>L</sub> after &#x003b1;-CD3 administration (Fig. <xref ref-type="fig" rid="F9">9</xref> D). Taken together, these results demonstrated that the in vivo administration of &#x003b1;-CD3 mAb resulted in the specific downregulation of the antiapoptotic gene <italic>bcl-x<sub>L</sub></italic> in DP thymocytes and that this reduced expression of Bcl-x<sub>L</sub> was, in turn, associated with subsequent apoptotic cell death. In contrast, DP thymocytes from mI&#x003ba;B-&#x003b1; mice failed to downregulate Bcl-x<sub>L</sub> and were protected from &#x003b1;-CD3&#x02013;mediated programmed cell death.</p></sec></sec><sec id="Discussion"><title>Discussion</title><p>In the studies described in this report, we have used transgenic mice expressing a superinhibitory form of I&#x003ba;B-&#x003b1; to study the function of NF-&#x003ba;B in T cells in vivo. The dominant-negative approach used in these studies circumvents potential problems of functional redundancy and embryonic lethality that can complicate the analysis of gene targeting experiments. In addition, because the transgene is only expressed in thymocytes and T cells we can conclude that the observed defects in T cell function are thymocyte or T cell autonomous. Our results have revealed several important roles for NF-&#x003ba;B proteins in T cell development and function. First in agreement with previous reports (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B46" ref-type="bibr">46</xref>) we showed that NF-&#x003ba;B is required for the development and/or survival of normal numbers of peripheral CD8<sup>+</sup> T cells, for the inducible expression of multiple cytokine genes, and for normal T cell proliferation in response to TCR-mediated T cell activation. However, our studies have also revealed an unexpected and novel role for NF-&#x003ba;B proteins in DP thymocyte apoptosis in response to &#x003b1;-CD3 mAb administration in vivo.</p><sec disp-level="4"><title>Defective Thymocyte Proliferation and Cytokine Production in the mI&#x003ba;B-&#x003b1; Mice.</title><p>TCR engagement leads to the precisely orchestrated transcriptional induction of &#x0003e;100 new genes whose expression together determine the activated T cell phenotype. Several inducible transcription factors have been implicated as critical early regulators of activation-specific T cell gene expression. These include NF-AT, CREB, AP1, and NF-&#x003ba;B (<xref rid="B60" ref-type="bibr">60</xref>). Three of these, NF-AT, CREB, and NF-&#x003ba;B, are present in an inactive form in resting T cells and are activated by posttranslational phosphorylation or dephosphorylation in response to TCR cross-linking. The precise role of each of these transcription factors in regulating T cell activation remains unclear because many T cell genes contain binding sites for multiple inducible transcription factors, and because it has been difficult to extrapolate from the results of transient transfection assays performed in immortalized T cell lines to in vivo transcriptional regulatory pathways. Thus, for example, NF-AT, AP1, and NF-&#x003ba;B transcription factors can each bind to functionally important sites in the IL-2 promoter in vitro (<xref rid="B71" ref-type="bibr">71</xref>&#x02013;<xref rid="B74" ref-type="bibr">74</xref>). Moreover, transient transfection assays have suggested that each of these transcription factors may play an important role in regulating the expression of this T cell cytokine (<xref rid="B75" ref-type="bibr">75</xref>&#x02013;<xref rid="B76" ref-type="bibr">76</xref>). However, gene targeting experiments have thus far failed to demonstrate a critical role for NF-AT in positively regulating IL-2 expression and T cell proliferation in normal T cells (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). To circumvent these problems, we used a genetic approach involving overexpression of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> in transgenic mice to directly study the role of NF-&#x003ba;B proteins in the development and activation of normal T cells in vivo. Our results demonstrated that NF-&#x003ba;B is required for the inducible expression of the IL-2, IL-3, and GM-CSF genes and for subsequent T cell proliferation in response to TCR stimulation. These findings are consistent with similar defects in cytokine production and T cell proliferation observed in mice lacking the c-Rel protein (<xref rid="B29" ref-type="bibr">29</xref>) or expressing a constitutively active I&#x003ba;B-&#x003b1; transgenic protein containing an NH<sub>2</sub>-terminal deletion (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>Previous studies have suggested that the CD28 costimulatory pathway functions to activate cytokine gene transcription via an NF-&#x003ba;B&#x02013;mediated signaling pathway (<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B79" ref-type="bibr">79</xref>&#x02013;<xref rid="B81" ref-type="bibr">81</xref>). Interestingly, however, we and others (<xref rid="B33" ref-type="bibr">33</xref>) found that the inhibitory effects of I&#x003ba;B-&#x003b1;<sub>A32/36</sub> on &#x003b1;-CD3&#x02013;mediated thymocyte proliferation could be partially reversed by &#x003b1;-CD28&#x02013;mediated costimulation. This suggests that at least some of the costimulatory effects of the CD28 pathway are mediated via one or more NF-&#x003ba;B&#x02013;independent pathways. In this regard, it is of interest that &#x003b1;-CD28 costimulation has also been reported to increase IL-2 expression by stabilizing IL-2 mRNA (<xref rid="B82" ref-type="bibr">82</xref>). It will be of interest to determine if this mRNA-stabilizing effect of CD28 signaling is regulated via an NF-&#x003ba;B&#x02013;independent pathway.</p><p>The mechanism responsible for the observed reduction in peripheral CD8<sup>+</sup> T cells in the mI&#x003ba;B-&#x003b1; mice remains unclear. It may reflect unique roles for NF-&#x003ba;B in the signaling pathways required for the maturation or export of mature CD8<sup>+</sup> thymocytes. Alternatively, it may reflect a defect in the survival of CD8<sup>+</sup> T cells in the periphery of the mI&#x003ba;B-&#x003b1; mice. In this regard, it is of interest that the survival of peripheral naive SP CD8<sup>+</sup> T cells has been reported to require continuous stimulation by class I MHC. Thus, it is possible that this class I MHC&#x02013;mediated signal is transmitted through an NF-&#x003ba;B&#x02013;dependent pathway (<xref rid="B83" ref-type="bibr">83</xref>).</p></sec><sec disp-level="4"><title>The Role of NF-&#x003ba;B in DP Thymocyte Apoptosis.</title><p> Pro grammed cell death plays an important role in shaping the T cell repertoire during thymocyte ontogeny. More than 95% of immature DP thymocytes die before they exit the thymus (<xref rid="B84" ref-type="bibr">84</xref>). Thymocytes that express TCRs with low avidity for antigen plus self-MHC fail to be positively selected and die by &#x0201c;neglect&#x0201d;, whereas self-reactive DP T cells are deleted during the process of negative selection after high affinity engagement of their TCRs by self-antigenic peptides and MHC (<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>). Our results demonstrate that NF-&#x003ba;B proteins are necessary positive mediators of DP thymocyte apoptosis in response to &#x003b1;-CD3 administration in vivo. These findings were somewhat surprising given several recent studies that have reported that NF-&#x003ba;B proteins are potent inhibitors of TNF-&#x003b1;&#x02013; and IL-1&#x02013;mediated apoptosis in fibroblasts (<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B87" ref-type="bibr">87</xref>). However, our findings are consistent with previous reports demonstrating that NF-&#x003ba;B proteins can positively regulate apoptosis in certain cell types in vitro including thymocytes and T cell hybridomas (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B44" ref-type="bibr">44</xref>). The different findings of these studies may reflect the fact that NF-&#x003ba;B can regulate the expression of distinct proapoptotic and antiapoptotic programs in different cell lineages, at different developmental stages of a single lineage, and/or in response to different extracellular signals.</p><p>At least three different apoptotic pathways have been identified in thymocytes: (a) a TCR-mediated pathway (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B88" ref-type="bibr">88</xref>); (b) a glucocorticoid-responsive pathway (<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>); and (c) a &#x003b3; irradiation&#x02013;sensitive pathway (<xref rid="B64" ref-type="bibr">64</xref>). Recent evidence has suggested that these pathways can be distinguished at a molecular level. Thus, for example, &#x003b3; irradiation&#x02013;induced thymocyte apoptosis requires p53 and does not occur in p53-deficient thymocytes. In contrast, &#x003b1;-CD3&#x02013;mediated thymocyte apoptosis is p53 independent (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B91" ref-type="bibr">91</xref>). Our results are consistent with such a model in that the mI&#x003ba;B-&#x003b1; DP thymocytes were protected from &#x003b1;-CD3&#x02013;induced apoptosis but remained sensitive to programmed cell death induced by &#x003b3; irradiation. Thus, we would suggest that NF-&#x003ba;B is not required for p53-dependent thymocyte apoptosis, but is a critical positive regulator of at least one p53-independent pathway of programmed cell death in DP thymocytes. In this regard, it will be of interest to study DP thymocyte apoptosis in p53-deficient, mI&#x003ba;B-&#x003b1; transgenic mice.</p><p>Our results suggest that NF-&#x003ba;B mediates &#x003b1;-CD3&#x02013;mediated apoptosis in wild-type DP thymoctyes by downregulating the expression of the antiapoptotic gene <italic>bcl-x<sub>L</sub></italic>. Because <italic>bcl-x<sub>L</sub></italic> is the predominant antiapoptotic gene expressed in DP thymocytes (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>) it is not surprising that its downregulation would predispose these cells to apoptosis. Such a model is also consistent with previous studies that have demonstrated that constitutive expression of a <italic>bcl-x<sub>L</sub></italic> transgene in DP thymocytes protects them from &#x003b1;-CD3&#x02013;mediated apoptosis (<xref rid="B69" ref-type="bibr">69</xref>). Recently, an alternatively spliced form of <italic>bcl-x<sub>L</sub></italic> called <italic>bcl-x<sub>&#x003b3;</sub></italic> has been shown to be expressed in DP thymocytes and to be regulated in response to TCR stimulation (<xref rid="B92" ref-type="bibr">92</xref>). Because the Bcl-x<sub>L</sub> and Bcl-x<sub>&#x003b3;</sub> proteins are virtually identical in size and are both recognized by the anti-Bcl-x<sub>L</sub> antibodies and probes used in our studies, we cannot distinguish them by RNAse protection, Western blotting, or intracellular flow cytometry. Thus, it is possible that one or both isoforms of Bcl-x contribute to the antiapoptotic effects of the I&#x003ba;B-&#x003b1;<sub>A32/36</sub> transgene. The effect of NF-&#x003ba;B on Bcl-x<sub>L</sub> expression in DP thymocytes may be direct or indirect. That is, NF-&#x003ba;B proteins might bind directly to the <italic>bcl-x<sub>L</sub></italic> promoter and downregulate its activity, or alternatively, might control the expression of other (positive and/or negative) regulators of the <italic>bcl-x<sub>L</sub></italic> gene in thymocytes. In this regard, it will be of interest to further characterize the <italic>bcl-x<sub>L</sub></italic> promoter and to study its regulation by NF-&#x003ba;B proteins.</p><p>It is important to emphasize that at present, we cannot conclude that the proapoptotic effects of NF-&#x003ba;B in DP thymocytes are thymocyte autonomous. For example, it is possible that &#x003b1;-CD3 administration causes peripheral T cell activation resulting in cytokine expression that in a paracrine fashion causes DP thymocyte toxicity (<xref rid="B93" ref-type="bibr">93</xref>). In such a model, decreased cytokine production by peripheral mI&#x003ba;B-&#x003b1; T cells in response to &#x003b1;-CD3 treatment could account for the decreased DP thymocyte apoptosis seen in these animals. Indeed our results demonstrate decreased cytokine production by thymocytes after TCR cross-linking (Fig. <xref ref-type="fig" rid="F5">5</xref>). However, this non&#x02013;thymocyte-autonomous model is less likely to account for the resistance to &#x003b1;-CD3&#x02013;induced thymocyte death seen in the mI&#x003ba;B-&#x003b1; mice because DP thymocytes from the mI&#x003ba;B-&#x003b1; mice are also resistant to &#x003b1;-CD3&#x02013;mediated killing in FTOC. Thus, it would appear more likely that NF-&#x003ba;B expression in DP thymocytes is directly required for &#x003b1;-CD3&#x02013;induced apoptosis.</p><p>During the last several years, there has been considerable interest in developing inhibitors of NF-&#x003ba;B for the treatment of both autoimmune diseases and cancer. In the case of cancer, such inhibitors might function to increase the sensitivity of tumor cells to apoptotic cell death induced both by cytokines such as TNF-&#x003b1; and by CTLs. In patients with autoimmune disease, such inhibitors might function by suppressing T cell activation in response to self-antigens. Our finding that NF-&#x003ba;B can function to potentiate apoptosis in certain cell types and specifically in DP thymocytes raises several potential concerns about the systemic administration of NF-&#x003ba;B inhibitors. First, it is possible that some tumor cells and/or virus-infected cells, like DP thymocytes, may actually demonstrate decreased apoptosis in response to NF-&#x003ba;B inhibitors. Thus, it is possible that potent NF-&#x003ba;B inhibitors might potentiate tumorgenesis in some tissues and might also reduce host responses against viral pathogens by decreasing susceptibility to apoptosis. Similarly, our finding that NF-&#x003ba;B inhibitors protect DP thymocytes from apoptosis suggests the possibility that the administration of such inhibitors to patients with autoimmune diseases might result in a failure in the negative selection of some DP thymocytes, thereby potentially increasing the generation of autoreactive T cell clones. Given these possibilities, it will be important to carefully assess the effects of NF-&#x003ba;B inhibitors on the apoptotic potential of different human tumor and virus-infected cells and on the negative selection of DP thymocytes before their wide-spread use in human therapy.</p></sec></sec></body><back><ack><p>We thank C. Clendenin for help with the production of transgenic mice, J. Auger for technical assistance with FACS<sup>&#x000ae;</sup> analyses, and P. Lawrey and L. Gottschalk for help with the preparation of the manuscript and illustrations.</p></ack><fn-group><fn><p>Thore Hettmann is a Terry Fox Research Fellow. This work was supported in part by a grant from the NIAID to J.M. Leiden (2 R37 A129637-07) and by the Cancer Center of the University of Chicago, and by a grant from the NIAID to M. Karin (R01 AI43477-01).</p></fn></fn-group><glossary><title>Abbreviations used in this paper</title><def-list><def-item><term>EMSA</term><def><p>electrophoretic mobility shift assay</p></def></def-item><def-item><term>FTOC</term><def><p>fetal thymic organ culture</p></def></def-item><def-item><term>HA</term><def><p>hemagglutinin</p></def></def-item><def-item><term>I&#x003ba;B-&#x003b1;</term><def><p>inhibitor &#x003ba;B-&#x003b1;</p></def></def-item><def-item><term>mI&#x003ba;B-&#x003b1;</term><def><p>mutant I&#x003ba;B-&#x003b1;</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p>nuclear factor &#x003ba;B</p></def></def-item><def-item><term>TUNEL</term><def><p>Tdt-mediated dUTP nick end labeling</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grilli</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>JJ-S</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group>
<article-title>NF-&#x003ba;B and Rel: participants in a multiform transcriptional regulatory system</article-title>
<source>Int Rev Cytol</source>
<year>1993</year>
<volume>143</volume>
<fpage>1</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">8449662</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Henkel</surname><given-names>T</given-names></name></person-group>
<article-title>Function and activation of NF-kappa B in the immune system</article-title>
<source>Annu Rev Immunol</source>
<year>1994</year>
<volume>12</volume>
<fpage>141</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">8011280</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>AS</given-names></name></person-group>
<article-title>The NF-&#x003ba;B and I&#x003ba;B proteins: new discoveries and insights</article-title>
<source>Annu Rev Immunol</source>
<year>1996</year>
<volume>14</volume>
<fpage>649</fpage>
<lpage>681</lpage>
<pub-id pub-id-type="pmid">8717528</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>May</surname><given-names>MJ</given-names></name><name><surname>Kopp</surname><given-names>EB</given-names></name></person-group>
<article-title>NF-&#x003ba;B and Rel proteins: evolutionary conserved mediators of immune responses</article-title>
<source>Annu Rev Immunol</source>
<year>1998</year>
<volume>16</volume>
<fpage>225</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="pmid">9597130</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siebenlist</surname><given-names>U</given-names></name><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group>
<article-title>Structure, regulation and function of NF-kappa B</article-title>
<source>Annu Rev Cell Biol</source>
<year>1994</year>
<volume>10</volume>
<fpage>405</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">7888182</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kunsch</surname><given-names>C</given-names></name><name><surname>Ruben</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>C</given-names></name></person-group>
<article-title>Selection of optimal &#x003ba;B-Rel DNA-binding motifs: interaction of both subunits of NF-&#x003ba;B with DNA is required for transcriptional activation</article-title>
<source>Mol Cell Biol</source>
<year>1992</year>
<volume>12</volume>
<fpage>4412</fpage>
<lpage>4421</lpage>
<pub-id pub-id-type="pmid">1406630</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verma</surname><given-names>IM</given-names></name><name><surname>Stevenson</surname><given-names>JK</given-names></name><name><surname>Schwarz</surname><given-names>EM</given-names></name><name><surname>Van Antwerp</surname><given-names>D</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name></person-group>
<article-title>Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation</article-title>
<source>Genes Dev</source>
<year>1995</year>
<volume>9</volume>
<fpage>2723</fpage>
<lpage>2735</lpage>
<pub-id pub-id-type="pmid">7590248</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Finco</surname><given-names>TS</given-names></name><name><surname>Nantermet</surname><given-names>PV</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation</article-title>
<source>Mol Cell Biol</source>
<year>1993</year>
<volume>13</volume>
<fpage>3301</fpage>
<lpage>3310</lpage>
<pub-id pub-id-type="pmid">8497253</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kanno</surname><given-names>T</given-names></name><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group>
<article-title>Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1993</year>
<volume>90</volume>
<fpage>2532</fpage>
<lpage>2536</lpage>
<pub-id pub-id-type="pmid">8460169</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henkel</surname><given-names>T</given-names></name><name><surname>Machleidt</surname><given-names>T</given-names></name><name><surname>Alkalay</surname><given-names>I</given-names></name><name><surname>Kronke</surname><given-names>M</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group>
<article-title>Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B</article-title>
<source>Nature</source>
<year>1993</year>
<volume>365</volume>
<fpage>182</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="pmid">8371761</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H</given-names></name><name><surname>Tempst</surname><given-names>P</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group>
<article-title>I&#x003ba;B-&#x003b2; regulates the persistent response in a biphasic activation of NF-&#x003ba;B</article-title>
<source>Cell</source>
<year>1995</year>
<volume>80</volume>
<fpage>573</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="pmid">7867065</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alkalay</surname><given-names>I</given-names></name><name><surname>Yaron</surname><given-names>A</given-names></name><name><surname>Hatzubai</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Avraham</surname><given-names>A</given-names></name><name><surname>Gerlitz</surname><given-names>O</given-names></name><name><surname>Pashut-Lavon</surname><given-names>L</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name></person-group>
<article-title>In vivo stimulation of I&#x003ba;B phosphorylation is not sufficient to activate NF-&#x003ba;B</article-title>
<source>Mol Cell Biol</source>
<year>1995</year>
<volume>15</volume>
<fpage>1294</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="pmid">7862123</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DiDonato</surname><given-names>JA</given-names></name><name><surname>Mercurio</surname><given-names>F</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group>
<article-title>Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B</article-title>
<source>Mol Cell Biol</source>
<year>1995</year>
<volume>15</volume>
<fpage>1302</fpage>
<lpage>1311</lpage>
<pub-id pub-id-type="pmid">7862124</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group>
<article-title>Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1995</year>
<volume>92</volume>
<fpage>552</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="pmid">7831327</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Gerstberger</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>L</given-names></name><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group>
<article-title>Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation</article-title>
<source>Science</source>
<year>1995</year>
<volume>267</volume>
<fpage>1485</fpage>
<lpage>1488</lpage>
<pub-id pub-id-type="pmid">7878466</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Traenckner</surname><given-names>EB</given-names></name><name><surname>Pahl</surname><given-names>HL</given-names></name><name><surname>Henkel</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>KN</given-names></name><name><surname>Wilk</surname><given-names>S</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group>
<article-title>Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli</article-title>
<source>EMBO (Eur Mol Biol Organ) J</source>
<year>1995</year>
<volume>14</volume>
<fpage>2876</fpage>
<lpage>2883</lpage>
<pub-id pub-id-type="pmid">7796813</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scherer</surname><given-names>DC</given-names></name><name><surname>Brockman</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Ballard</surname><given-names>DW</given-names></name></person-group>
<article-title>Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1995</year>
<volume>92</volume>
<fpage>11259</fpage>
<lpage>11263</lpage>
<pub-id pub-id-type="pmid">7479976</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Hagler</surname><given-names>J</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Melandri</surname><given-names>F</given-names></name><name><surname>Scherer</surname><given-names>D</given-names></name><name><surname>Ballard</surname><given-names>D</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group>
<article-title>Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway</article-title>
<source>Genes Dev</source>
<year>1995</year>
<volume>9</volume>
<fpage>1586</fpage>
<lpage>1597</lpage>
<pub-id pub-id-type="pmid">7628694</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sen</surname><given-names>J</given-names></name><name><surname>Venkataraman</surname><given-names>L</given-names></name><name><surname>Shinkai</surname><given-names>Y</given-names></name><name><surname>Pierce</surname><given-names>JW</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Burakoff</surname><given-names>SJ</given-names></name><name><surname>Sen</surname><given-names>R</given-names></name></person-group>
<article-title>Expression and induction of nuclear factor-kappa B-related proteins in thymocytes</article-title>
<source>J Immunol</source>
<year>1995</year>
<volume>154</volume>
<fpage>3213</fpage>
<lpage>3221</lpage>
<pub-id pub-id-type="pmid">7534792</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name></person-group>
<article-title>Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen</article-title>
<source>Oncogene</source>
<year>1994</year>
<volume>9</volume>
<fpage>3289</fpage>
<lpage>3297</lpage>
<pub-id pub-id-type="pmid">7936653</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feuillard</surname><given-names>J</given-names></name><name><surname>Dargemont</surname><given-names>C</given-names></name><name><surname>Ferreira</surname><given-names>V</given-names></name><name><surname>Tarantino</surname><given-names>N</given-names></name><name><surname>Debre</surname><given-names>P</given-names></name><name><surname>Raphael</surname><given-names>M</given-names></name><name><surname>Korner</surname><given-names>M</given-names></name></person-group>
<article-title>Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes</article-title>
<source>J Immunol</source>
<year>1997</year>
<volume>158</volume>
<fpage>2585</fpage>
<lpage>2591</lpage>
<pub-id pub-id-type="pmid">9058790</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Rothenberg</surname><given-names>EV</given-names></name></person-group>
<article-title>Molcular basis for developmental changes in Interleukin-2 gene inducibility</article-title>
<source>Mol Cell Biol</source>
<year>1993</year>
<volume>13</volume>
<fpage>228</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="pmid">8417328</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>S-M</given-names></name><name><surname>Tran</surname><given-names>A-C</given-names></name><name><surname>Grilli</surname><given-names>M</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group>
<article-title>NF-&#x003ba;B subunit regulation in nontransformed CD4<sup>+</sup>T-lymphocytes</article-title>
<source>Science</source>
<year>1992</year>
<volume>256</volume>
<fpage>1452</fpage>
<lpage>1456</lpage>
<pub-id pub-id-type="pmid">1604322</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Liou</surname><given-names>HC</given-names></name><name><surname>Tuomanen</surname><given-names>EI</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses</article-title>
<source>Cell</source>
<year>1995</year>
<volume>80</volume>
<fpage>321</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">7834752</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Snapper</surname><given-names>CM</given-names></name><name><surname>Zelazowski</surname><given-names>P</given-names></name><name><surname>Rosas</surname><given-names>FR</given-names></name><name><surname>Kehry</surname><given-names>MR</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Sha</surname><given-names>WC</given-names></name></person-group>
<article-title>B cells from p50/ NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching</article-title>
<source>J Immunol</source>
<year>1996</year>
<volume>156</volume>
<fpage>183</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="pmid">8598461</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burkly</surname><given-names>L</given-names></name><name><surname>Hession</surname><given-names>C</given-names></name><name><surname>Ogata</surname><given-names>L</given-names></name><name><surname>Reilly</surname><given-names>C</given-names></name><name><surname>Marconi</surname><given-names>LA</given-names></name><name><surname>Olson</surname><given-names>D</given-names></name><name><surname>Tizard</surname><given-names>R</given-names></name><name><surname>Cate</surname><given-names>R</given-names></name><name><surname>Lo</surname><given-names>D</given-names></name></person-group>
<article-title>Expression of <italic>relB</italic>is required for the development of thymic medulla and dendritic cells</article-title>
<source>Nature</source>
<year>1995</year>
<volume>373</volume>
<fpage>531</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="pmid">7845467</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Durham</surname><given-names>SK</given-names></name><name><surname>Barton</surname><given-names>DS</given-names></name><name><surname>Rizzo</surname><given-names>CA</given-names></name><name><surname>Ryseck</surname><given-names>RP</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name></person-group>
<article-title>Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family</article-title>
<source>Cell</source>
<year>1995</year>
<volume>80</volume>
<fpage>331</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">7834753</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Durham</surname><given-names>SK</given-names></name><name><surname>Barton</surname><given-names>DS</given-names></name><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name></person-group>
<article-title>p50-NF-&#x003ba;B complexes partially compensate for the absence of RelB severely increased pathology in p50<sup>&#x02212;/&#x02212;</sup>relB<sup>&#x02212;/&#x02212;</sup>double knockout mice</article-title>
<source>J Exp Med</source>
<year>1997</year>
<volume>185</volume>
<fpage>1359</fpage>
<lpage>1370</lpage>
<pub-id pub-id-type="pmid">9104822</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kontgen</surname><given-names>F</given-names></name><name><surname>Grumont</surname><given-names>RJ</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Tarlinton</surname><given-names>D</given-names></name><name><surname>Gerondakis</surname><given-names>S</given-names></name></person-group>
<article-title>Mice lacking the c-<italic>rel</italic>proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression</article-title>
<source>Genes Dev</source>
<year>1995</year>
<volume>9</volume>
<fpage>1965</fpage>
<lpage>1977</lpage>
<pub-id pub-id-type="pmid">7649478</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doi</surname><given-names>TS</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Tagushi</surname><given-names>O</given-names></name><name><surname>Azuma</surname><given-names>T</given-names></name><name><surname>Obata</surname><given-names>Y</given-names></name></person-group>
<article-title>NF-&#x003ba;B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative response</article-title>
<source>J Exp Med</source>
<year>1997</year>
<volume>185</volume>
<fpage>953</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="pmid">9120401</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B</article-title>
<source>Nature</source>
<year>1995</year>
<volume>376</volume>
<fpage>167</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">7603567</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>BH</given-names></name><name><surname>Scott</surname><given-names>ML</given-names></name><name><surname>Cherry</surname><given-names>SR</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>Failure of lymphopoiesis after adoptive transfer of NF-&#x003ba;B-deficient fetal liver cells</article-title>
<source>Immunity</source>
<year>1997</year>
<volume>6</volume>
<fpage>765</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="pmid">9208848</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boothby</surname><given-names>MR</given-names></name><name><surname>Mora</surname><given-names>AL</given-names></name><name><surname>Scherer</surname><given-names>DC</given-names></name><name><surname>Brockman</surname><given-names>JA</given-names></name><name><surname>Ballard</surname><given-names>DW</given-names></name></person-group>
<article-title>Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-&#x003ba;B</article-title>
<source>J Exp Med</source>
<year>1997</year>
<volume>185</volume>
<fpage>1897</fpage>
<lpage>1907</lpage>
<pub-id pub-id-type="pmid">9166419</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arsura</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Sonnenshein</surname><given-names>GE</given-names></name></person-group>
<article-title>TGF&#x003b2;1 inhibits NF-&#x003ba;B/Rel activity inducing apoptosis of B cells: transcriptional activation of I&#x003ba;B&#x003b1;</article-title>
<source>Immunity</source>
<year>1996</year>
<volume>5</volume>
<fpage>31</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">8758892</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Arsura</surname><given-names>M</given-names></name><name><surname>Bellas</surname><given-names>RE</given-names></name><name><surname>FitzGerald</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Schauer</surname><given-names>S</given-names></name><name><surname>Sherr</surname><given-names>DH</given-names></name><name><surname>Sonnenshein</surname><given-names>GE</given-names></name></person-group>
<article-title>Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells</article-title>
<source>Mol Cell Biol</source>
<year>1996</year>
<volume>16</volume>
<fpage>5015</fpage>
<lpage>5025</lpage>
<pub-id pub-id-type="pmid">8756660</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>An essential role for NF-&#x003ba;B in preventing TNF-&#x003b1;-induced cell death</article-title>
<source>Science</source>
<year>1996</year>
<volume>274</volume>
<fpage>782</fpage>
<lpage>784</lpage>
<pub-id pub-id-type="pmid">8864118</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Antwerp</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Kafri</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group>
<article-title>Suppression of TNF-&#x003b1;-induced apoptosis by NF-&#x003ba;B</article-title>
<source>Science</source>
<year>1996</year>
<volume>274</volume>
<fpage>787</fpage>
<lpage>789</lpage>
<pub-id pub-id-type="pmid">8864120</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Mayo</surname><given-names>MW</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names></name></person-group>
<article-title>TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-&#x003ba;B</article-title>
<source>Science</source>
<year>1996</year>
<volume>274</volume>
<fpage>784</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="pmid">8864119</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z-g</given-names></name><name><surname>Hsu</surname><given-names>H</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group>
<article-title>Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-&#x003ba;B activation prevents cell death</article-title>
<source>Cell</source>
<year>1996</year>
<volume>87</volume>
<fpage>565</fpage>
<lpage>576</lpage>
<pub-id pub-id-type="pmid">8898208</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grimm</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>MK</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Schulze</surname><given-names>K</given-names></name></person-group>
<collab>- Osthoff</collab>
<article-title>Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis</article-title>
<source>J Cell Biol</source>
<year>1996</year>
<volume>134</volume>
<fpage>13</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">8698809</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Dritschilo</surname><given-names>A</given-names></name></person-group>
<article-title>Correction of radiation sensitivity in ataxia telangiectasia by a truncated I&#x003ba;B-&#x003b1;</article-title>
<source>Science</source>
<year>1995</year>
<volume>268</volume>
<fpage>1619</fpage>
<lpage>1621</lpage>
<pub-id pub-id-type="pmid">7777860</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bessho</surname><given-names>R</given-names></name><name><surname>Matsubara</surname><given-names>K</given-names></name><name><surname>Kubot</surname><given-names>M</given-names></name><name><surname>Kuwakado</surname><given-names>K</given-names></name><name><surname>Hirota</surname><given-names>H</given-names></name><name><surname>Wakazono</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Lin</surname></name><name><surname>Okuda</surname><given-names>A</given-names></name><name><surname>Kawai</surname><given-names>M</given-names></name><name><surname>Nishikomoro</surname><given-names>R</given-names></name><name><surname>Heike</surname><given-names>T</given-names></name></person-group>
<article-title>Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor &#x003ba;B (NF-&#x003ba;B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes</article-title>
<source>Biochem Pharmacol</source>
<year>1994</year>
<volume>48</volume>
<fpage>1883</fpage>
<lpage>1889</lpage>
<pub-id pub-id-type="pmid">7986199</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grilli</surname><given-names>M</given-names></name><name><surname>Pizzi</surname><given-names>M</given-names></name><name><surname>Memo</surname><given-names>M</given-names></name><name><surname>Spano</surname><given-names>PF</given-names></name></person-group>
<article-title>Neuroproduction by aspirin and sodium salicylate through blockade by NF-&#x003ba;B activation</article-title>
<source>Science</source>
<year>1996</year>
<volume>274</volume>
<fpage>1383</fpage>
<lpage>1385</lpage>
<pub-id pub-id-type="pmid">8910280</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>VN</given-names></name><name><surname>Lee</surname><given-names>RK</given-names></name><name><surname>Podack</surname><given-names>ER</given-names></name><name><surname>Malek</surname><given-names>TR</given-names></name></person-group>
<article-title>Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF-&#x003ba;B</article-title>
<source>Oncogene</source>
<year>1997</year>
<volume>14</volume>
<fpage>2455</fpage>
<lpage>2464</lpage>
<pub-id pub-id-type="pmid">9188860</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbadie</surname><given-names>C</given-names></name><name><surname>Kabrun</surname><given-names>N</given-names></name><name><surname>Bouali</surname><given-names>F</given-names></name><name><surname>Smardova</surname><given-names>J</given-names></name><name><surname>Stehelin</surname><given-names>D</given-names></name><name><surname>Banderbunder</surname><given-names>B</given-names></name><name><surname>Enrietto</surname><given-names>PJ</given-names></name></person-group>
<article-title>High level of c-Rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells <italic>in vitro. </italic>
</article-title>
<source>Cell</source>
<year>1993</year>
<volume>75</volume>
<fpage>899</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="pmid">8252626</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esslinger</surname><given-names>CW</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Sordat</surname><given-names>B</given-names></name><name><surname>Beermann</surname><given-names>F</given-names></name><name><surname>Jongeneel</surname><given-names>CV</given-names></name></person-group>
<article-title>Abnormal T cell development induced by targeted overexpression of I&#x003ba;B&#x003b1;</article-title>
<source>J Immunol</source>
<year>1997</year>
<volume>158</volume>
<fpage>5075</fpage>
<lpage>5078</lpage>
<pub-id pub-id-type="pmid">9164919</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DiDonato</surname><given-names>J</given-names></name><name><surname>Mercurio</surname><given-names>F</given-names></name><name><surname>Rosette</surname><given-names>C</given-names></name><name><surname>Wu-Li</surname><given-names>J</given-names></name><name><surname>Suyang</surname><given-names>H</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group>
<article-title>Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation</article-title>
<source>Mol Cell Biol</source>
<year>1996</year>
<volume>16</volume>
<fpage>1295</fpage>
<lpage>1304</lpage>
<pub-id pub-id-type="pmid">8657102</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lake</surname><given-names>RA</given-names></name><name><surname>Wotton</surname><given-names>D</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name></person-group>
<article-title>A 3&#x02032; transcriptional enhancer regulates tissue-specific expression of the human CD2 gene</article-title>
<source>EMBO (Eur Mol Biol Organ) J</source>
<year>1990</year>
<volume>9</volume>
<fpage>3129</fpage>
<lpage>3136</lpage>
<pub-id pub-id-type="pmid">2209539</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Bassuk</surname><given-names>AG</given-names></name><name><surname>Boise</surname><given-names>LH</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name><name><surname>Leiden</surname><given-names>JM</given-names></name></person-group>
<article-title>Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors</article-title>
<source>Mol Cell Biol</source>
<year>1994</year>
<volume>14</volume>
<fpage>1153</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="pmid">8289796</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ballard</surname><given-names>DW</given-names></name><name><surname>Walker</surname><given-names>WH</given-names></name><name><surname>Doerre</surname><given-names>S</given-names></name><name><surname>Sista</surname><given-names>P</given-names></name><name><surname>Molitor</surname><given-names>JA</given-names></name><name><surname>Dixon</surname><given-names>EP</given-names></name><name><surname>Peffer</surname><given-names>NJ</given-names></name><name><surname>Hannink</surname><given-names>M</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group>
<article-title>The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function</article-title>
<source>Cell</source>
<year>1990</year>
<volume>63</volume>
<fpage>803</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="pmid">2225078</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gavrieli</surname><given-names>Y</given-names></name><name><surname>Sherman</surname><given-names>Y</given-names></name><name><surname>Ben-Sasson</surname><given-names>SA</given-names></name></person-group>
<article-title>Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation</article-title>
<source>J Cell Biol</source>
<year>1992</year>
<volume>119</volume>
<fpage>493</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="pmid">1400587</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finco</surname><given-names>TS</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names></name></person-group>
<article-title>Mechanistic aspects of NF-&#x003ba;B regulation: the emerging role of phosphorylation and proteolysis</article-title>
<source>Immunity</source>
<year>1995</year>
<volume>3</volume>
<fpage>263</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="pmid">7552992</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lang</surname><given-names>G</given-names></name><name><surname>Wotton</surname><given-names>D</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Sewell</surname><given-names>WA</given-names></name><name><surname>Brown</surname><given-names>MH</given-names></name><name><surname>Mason</surname><given-names>DY</given-names></name><name><surname>Crumpton</surname><given-names>MJ</given-names></name><name><surname>Kioussis</surname><given-names>D</given-names></name></person-group>
<article-title>The structure of the human CD2 gene and its expression in transgenic mice</article-title>
<source>EMBO (Eur Mol Biol Organ) J</source>
<year>1988</year>
<volume>7</volume>
<fpage>1675</fpage>
<lpage>1682</lpage>
<pub-id pub-id-type="pmid">2901953</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Jenkinson</surname><given-names>EJ</given-names></name><name><surname>Brown</surname><given-names>MH</given-names></name><name><surname>Sewell</surname><given-names>WA</given-names></name><name><surname>Krissansen</surname><given-names>GW</given-names></name><name><surname>Crumpton</surname><given-names>MJ</given-names></name><name><surname>Owen</surname><given-names>JJ</given-names></name></person-group>
<article-title>Murine CD2 gene expression during fetal thymus ontogeny</article-title>
<source>Eur J Immunol</source>
<year>1988</year>
<volume>18</volume>
<fpage>187</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="pmid">2450031</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolodziej</surname><given-names>PA</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group>
<article-title>Epitope tagging and protein surveillance</article-title>
<source>Methods Enzymol</source>
<year>1991</year>
<volume>194</volume>
<fpage>508</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="pmid">1706460</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moore</surname><given-names>NC</given-names></name><name><surname>Girdlestone</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Owen</surname><given-names>JT</given-names></name><name><surname>Jenkinson</surname><given-names>EJ</given-names></name></person-group>
<article-title>Stimulation of thymocytes before and after positive selection results in the induction of different NF-&#x003ba;B/Rel protein complexes</article-title>
<source>J Immunol</source>
<year>1995</year>
<volume>155</volume>
<fpage>4653</fpage>
<lpage>4660</lpage>
<pub-id pub-id-type="pmid">7594464</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nolan</surname><given-names>GP</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Bhatia</surname><given-names>K</given-names></name><name><surname>Huppi</surname><given-names>C</given-names></name><name><surname>Liou</surname><given-names>HC</given-names></name><name><surname>Scott</surname><given-names>ML</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner</article-title>
<source>Mol Cell Biol</source>
<year>1993</year>
<volume>13</volume>
<fpage>3557</fpage>
<lpage>3566</lpage>
<pub-id pub-id-type="pmid">8497270</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plaksin</surname><given-names>D</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Eisenbach</surname><given-names>L</given-names></name></person-group>
<article-title>&#x003ba;BF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2&#x003ba;B gene expression in metastatic tumor cells</article-title>
<source>J Exp Med</source>
<year>1993</year>
<volume>177</volume>
<fpage>1651</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="pmid">8496683</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verweij</surname><given-names>CL</given-names></name><name><surname>Geerts</surname><given-names>M</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name></person-group>
<article-title>Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-&#x003ba;B-like response element</article-title>
<source>J Biol Chem</source>
<year>1991</year>
<volume>266</volume>
<fpage>14179</fpage>
<lpage>14182</lpage>
<pub-id pub-id-type="pmid">1650350</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crabtree</surname><given-names>GR</given-names></name><name><surname>Clipstone</surname><given-names>NA</given-names></name></person-group>
<article-title>Signal transmission between the plasma mambrane and nucleus of T-lymphocytes</article-title>
<source>Annu Rev Biochem</source>
<year>1994</year>
<volume>63</volume>
<fpage>1045</fpage>
<lpage>1083</lpage>
<pub-id pub-id-type="pmid">7979236</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Bissonnette</surname><given-names>RP</given-names></name><name><surname>Parfrey</surname><given-names>N</given-names></name><name><surname>Szalay</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>RT</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group>
<article-title>In vivo administration of mononuclear antibodies to the CD3 T cell receptor complex induces cell death (apoptosis) in immature thymocytes</article-title>
<source>J Immunol</source>
<year>1991</year>
<volume>146</volume>
<fpage>3340</fpage>
<lpage>3346</lpage>
<pub-id pub-id-type="pmid">1827483</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tokoro</surname><given-names>Y</given-names></name><name><surname>Tsuda</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><name><surname>Takahama</surname><given-names>Y</given-names></name></person-group>
<article-title>CD3-induced apoptosis of CD4<sup>+</sup>CD8<sup>+</sup>thymocytes in the absence of clonotypic T cell antigen receptor</article-title>
<source>Eur J Immunol</source>
<year>1996</year>
<volume>26</volume>
<fpage>1012</fpage>
<lpage>1017</lpage>
<pub-id pub-id-type="pmid">8647161</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Williams</surname><given-names>AGT</given-names></name><name><surname>Kingston</surname><given-names>R</given-names></name><name><surname>Jenkinson</surname><given-names>EJ</given-names></name><name><surname>Owen</surname><given-names>JJT</given-names></name></person-group>
<article-title>Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures</article-title>
<source>Nature</source>
<year>1989</year>
<volume>337</volume>
<fpage>181</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">2521375</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>SW</given-names></name><name><surname>Osborne</surname><given-names>B</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group>
<article-title>p53 is required for radiation-induced apoptosis in mouse thymocytes</article-title>
<source>Nature</source>
<year>1993</year>
<volume>362</volume>
<fpage>847</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="pmid">8479522</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chao</surname><given-names>DT</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group>
<article-title>BCL-2 family: regulators of cell death</article-title>
<source>Annu Rev Immunol</source>
<year>1998</year>
<volume>16</volume>
<fpage>395</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="pmid">9597135</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gratiot-Deans</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name></person-group>
<article-title>bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic activation</article-title>
<source>J Immunol</source>
<year>1993</year>
<volume>151</volume>
<fpage>83</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">8326141</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veis</surname><given-names>DJ</given-names></name><name><surname>Sentman</surname><given-names>CL</given-names></name><name><surname>Bach</surname><given-names>EA</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group>
<article-title>Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes</article-title>
<source>J Immunol</source>
<year>1993</year>
<volume>151</volume>
<fpage>2546</fpage>
<lpage>2554</lpage>
<pub-id pub-id-type="pmid">8360476</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>Pena</surname><given-names>JC</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Margosian</surname><given-names>E</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>
<article-title>Bcl-x regulates the survival of double-positive thymocytes</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1995</year>
<volume>92</volume>
<fpage>4763</fpage>
<lpage>4767</lpage>
<pub-id pub-id-type="pmid">7761398</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grillot</surname><given-names>DA</given-names></name><name><surname>Merino</surname><given-names>R</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name></person-group>
<article-title>Bcl-X<sub>L</sub>displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice</article-title>
<source>J Exp Med</source>
<year>1995</year>
<volume>182</volume>
<fpage>1973</fpage>
<lpage>1983</lpage>
<pub-id pub-id-type="pmid">7500043</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chao</surname><given-names>DT</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Boise</surname><given-names>LH</given-names></name><name><surname>White</surname><given-names>LS</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group>
<article-title>Bcl-X<sub>L</sub>and Bcl-2 repress a common pathway of cell death</article-title>
<source>J Exp Med</source>
<year>1995</year>
<volume>182</volume>
<fpage>821</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="pmid">7650488</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durand</surname><given-names>DB</given-names></name><name><surname>Shaw</surname><given-names>J-P</given-names></name><name><surname>Bush</surname><given-names>MR</given-names></name><name><surname>Replogle</surname><given-names>RE</given-names></name><name><surname>Belagave</surname><given-names>R</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name></person-group>
<article-title>Characterization of antigen receptor response elements within the interleukin-2 enhancer</article-title>
<source>Mol Cell Biol</source>
<year>1988</year>
<volume>8</volume>
<fpage>1715</fpage>
<lpage>1720</lpage>
<pub-id pub-id-type="pmid">3260003</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ballard</surname><given-names>DW</given-names></name><name><surname>Bohnlein</surname><given-names>E</given-names></name><name><surname>Siekevitz</surname><given-names>M</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group>
<article-title>&#x003ba;B-specific DNA binding proteins: a role in the regulation of human interleukin-2 gene expression</article-title>
<source>Science</source>
<year>1989</year>
<volume>244</volume>
<fpage>457</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">2497518</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serfling</surname><given-names>E</given-names></name><name><surname>Avots</surname><given-names>A</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name></person-group>
<article-title>The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activtion</article-title>
<source>Biochem Biophys Acta</source>
<year>1995</year>
<volume>1263</volume>
<fpage>181</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">7548205</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group>
<article-title>Transcriptional regulation of the interleukin 2 gene</article-title>
<source>Curr Opin Immunol</source>
<year>1995</year>
<volume>7</volume>
<fpage>333</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">7546397</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shaw</surname><given-names>JP</given-names></name><name><surname>Utz</surname><given-names>PJ</given-names></name><name><surname>Durand</surname><given-names>DB</given-names></name><name><surname>Toole</surname><given-names>JJ</given-names></name><name><surname>Emmel</surname><given-names>EA</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name></person-group>
<article-title>Identification of a putative regulator of early T cell activation genes</article-title>
<source>Science</source>
<year>1988</year>
<volume>241</volume>
<fpage>202</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="pmid">3260404</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Miner</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group>
<article-title>Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells</article-title>
<source>J Immunol</source>
<year>1993</year>
<volume>151</volume>
<fpage>837</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="pmid">8335913</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hodge</surname><given-names>MR</given-names></name><name><surname>Ranger</surname><given-names>AM</given-names></name><name><surname>de la Brousse</surname><given-names>FC</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Grusby</surname><given-names>M</given-names></name><name><surname>Glimcher</surname><given-names>LH</given-names></name></person-group>
<article-title>Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice</article-title>
<source>Immunity</source>
<year>1996</year>
<volume>4</volume>
<fpage>397</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">8612134</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xanthoudakis</surname><given-names>S</given-names></name><name><surname>Viola</surname><given-names>JPB</given-names></name><name><surname>Shaw</surname><given-names>KTY</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Wallace</surname><given-names>JD</given-names></name><name><surname>Bozza</surname><given-names>PD</given-names></name><name><surname>Luk</surname><given-names>DC</given-names></name><name><surname>Curran</surname><given-names>T</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group>
<article-title>An enhanced immune response in mice lacking the transcription factor NFAT1</article-title>
<source>Science</source>
<year>1996</year>
<volume>272</volume>
<fpage>892</fpage>
<lpage>895</lpage>
<pub-id pub-id-type="pmid">8629027</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>JH</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name></person-group>
<article-title>CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin</article-title>
<source>J Biol Chem</source>
<year>1994</year>
<volume>269</volume>
<fpage>30077</fpage>
<lpage>30080</lpage>
<pub-id pub-id-type="pmid">7982907</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bryan</surname><given-names>RG</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>JH</given-names></name><name><surname>Van</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>NR</given-names></name><name><surname>Rich</surname><given-names>RR</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name></person-group>
<article-title>Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells</article-title>
<source>Mol Cell Biol</source>
<year>1994</year>
<volume>14</volume>
<fpage>7933</fpage>
<lpage>7942</lpage>
<pub-id pub-id-type="pmid">7969133</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name><name><surname>Rice</surname><given-names>NR</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name></person-group>
<article-title>The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1993</year>
<volume>90</volume>
<fpage>1696</fpage>
<lpage>1700</lpage>
<pub-id pub-id-type="pmid">8383323</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindsten</surname><given-names>T</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Stella</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>
<article-title>Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway</article-title>
<source>Science</source>
<year>1998</year>
<volume>244</volume>
<fpage>339</fpage>
<lpage>343</lpage>
</element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanchot</surname><given-names>C</given-names></name><name><surname>Lemonnier</surname><given-names>FA</given-names></name><name><surname>Perarnau</surname><given-names>B</given-names></name><name><surname>Freitas</surname><given-names>AA</given-names></name><name><surname>Rocha</surname><given-names>B</given-names></name></person-group>
<article-title>Differential requirements for survival and proliferation of CD8 naive or memory T cells</article-title>
<source>Science</source>
<year>1997</year>
<volume>276</volume>
<fpage>2057</fpage>
<lpage>2062</lpage>
<pub-id pub-id-type="pmid">9197272</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osborne</surname><given-names>BA</given-names></name></person-group>
<article-title>Apoptosis and maintenance of homeostasis in the immune system</article-title>
<source>Curr Opin Immunol</source>
<year>1996</year>
<volume>8</volume>
<fpage>245</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="pmid">8725948</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>PM</given-names></name></person-group>
<article-title>Peptides in negative and positive selection: a delicate balance</article-title>
<source>Cell</source>
<year>1994</year>
<volume>76</volume>
<fpage>593</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="pmid">8124703</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nossal</surname><given-names>GJV</given-names></name></person-group>
<article-title>Negative selection of lymphocytes</article-title>
<source>Cell</source>
<year>1994</year>
<volume>76</volume>
<fpage>229</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="pmid">8293461</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>NF-&#x003ba;B: ten years after</article-title>
<source>Cell</source>
<year>1996</year>
<volume>87</volume>
<fpage>13</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">8858144</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>EJ</given-names></name><name><surname>Kingston</surname><given-names>R</given-names></name><name><surname>Jenkinson</surname><given-names>EJ</given-names></name><name><surname>Owen</surname><given-names>JJT</given-names></name></person-group>
<article-title>Antigen-induced apoptosis in developing T cells: a mechanism for negative selection of the T cell repertoire</article-title>
<source>Eur J Immunol</source>
<year>1989</year>
<volume>19</volume>
<fpage>2175</fpage>
<lpage>2181</lpage>
<pub-id pub-id-type="pmid">2532142</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wyllie</surname><given-names>AH</given-names></name></person-group>
<article-title>Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation</article-title>
<source>Nature</source>
<year>1980</year>
<volume>284</volume>
<fpage>555</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="pmid">6245367</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JJ</given-names></name><name><surname>Duke</surname><given-names>RC</given-names></name></person-group>
<article-title>Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death</article-title>
<source>J Immunol</source>
<year>1984</year>
<volume>123</volume>
<fpage>38</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">6317746</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>AR</given-names></name><name><surname>Purdie</surname><given-names>CA</given-names></name><name><surname>Harrison</surname><given-names>DJ</given-names></name><name><surname>Morris</surname><given-names>RG</given-names></name><name><surname>Bird</surname><given-names>CC</given-names></name><name><surname>Hooper</surname><given-names>ML</given-names></name><name><surname>Wyllie</surname><given-names>AH</given-names></name></person-group>
<article-title>Thymocyte apoptosis induced by p53-dependent and independent pathways</article-title>
<source>Nature</source>
<year>1993</year>
<volume>362</volume>
<fpage>849</fpage>
<lpage>852</lpage>
<pub-id pub-id-type="pmid">8479523</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>X-F</given-names></name><name><surname>Weber</surname><given-names>GF</given-names></name><name><surname>Cantor</surname><given-names>H</given-names></name></person-group>
<article-title>A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells</article-title>
<source>Immunity</source>
<year>1997</year>
<volume>7</volume>
<fpage>629</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="pmid">9390687</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group>
<article-title>Interleukin-2 programs mouse &#x003b1;&#x003b2; T lymphocytes for apoptosis</article-title>
<source>Nature</source>
<year>1991</year>
<volume>353</volume>
<fpage>858</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="pmid">1944559</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haskill</surname><given-names>S</given-names></name><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Tompkins</surname><given-names>SM</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Yurochko</surname><given-names>AD</given-names></name><name><surname>Sampson-Johannes</surname><given-names>A</given-names></name><name><surname>Mondal</surname><given-names>K</given-names></name><name><surname>Ralph</surname><given-names>P</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity</article-title>
<source>Cell</source>
<year>1991</year>
<volume>65</volume>
<fpage>1281</fpage>
<lpage>1289</lpage>
<pub-id pub-id-type="pmid">1829648</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>Production of mI&#x003ba;B-&#x003b1; transgenic mice. (A) Schematic illustration of the I&#x003ba;B-&#x003b1;<sub>A32/36</sub> transgene. Nucleotide and amino acid sequences corresponding to amino acids 31 to 37 from the wild-type human I&#x003ba;B-&#x003b1; cDNA (<xref rid="B94" ref-type="bibr">94</xref>) and the mutant I&#x003ba;B-&#x003b1;<sub>A32/36</sub> are shown above the schematic representation of the transgene construct. Site-specific mutations within the I&#x003ba;B-&#x003b1;<sub>A32/36 </sub>cDNA sequence are underlined and the resulting Ser to Ala substitutions are circled. The HA epitope (HA), CD2 promoter (CD2-Pr), polyadenylation signal (poly A), and the CD2 enhancer/LCR (CD2 Enh) are also shown. (B) Southern blot analysis of tail DNA from wild-type (WT) and mI&#x003ba;B-&#x003b1; transgenic (Tg) mice was performed with a radiolabeled 0.8-kb I&#x003ba;B-&#x003b1; cDNA probe (see A) that hybridizes to both the transgene (I&#x003ba;B-&#x003b1;<sub>A32/36</sub>) and the endogenous I&#x003ba;B-&#x003b1; gene. Size markers in kilobases are shown to the right of the autoradiogram.</p></caption><graphic xlink:href="JEM981160.f1a"/><graphic xlink:href="JEM981160.f1b"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>I&#x003ba;B-&#x003b1; and NF-&#x003ba;B expression in the mI&#x003ba;B-&#x003b1; transgenic mice. (A) Western blot analysis of I&#x003ba;B-&#x003b1; expression in thymocytes from mI&#x003ba;B-&#x003b1; transgenic mice after treatment with TNF-&#x003b1;. Thymocytes from wild-type (WT) and mI&#x003ba;B-&#x003b1; transgenic (Tg) mice were incubated with TNF-&#x003b1; (15 ng/ml) for the indicated times and cytoplasmic extracts were separated by electrophoresis in a denaturing polyacrylamide gel. Proteins were transferred to a PDVF membrane and immunoblotted with either a murine HA-specific antibody (&#x003b1;-HA) or a rabbit polyclonal antibody specific for I&#x003ba;B-&#x003b1; (&#x003b1;-MAD) (<xref rid="B13" ref-type="bibr">13</xref>). The positions of the endogenous I&#x003ba;B-&#x003b1; and I&#x003ba;B-&#x003b1;<sub>A32/36</sub> transgene-encoded proteins are shown to the left of the autoradiogram. Size markers in kilodaltons are shown to the right of the autoradiogram. (B) EMSA of NF-&#x003ba;B expression in transgenic thymocytes after stimulation in vivo with &#x003b1;-CD3 mAb. Thymic nuclear extracts (2 &#x003bc;g) from mice treated for 3 h with a single intraperitoneal injection of &#x003b1;-CD3 mAb or PBS (control) were analyzed by EMSA with a radiolabeled &#x003ba;B oligonucleotide probe. For antibody supershift experiments, thymic nuclear extracts were preincubated with antibodies specific for NF-&#x003ba;B p50, p65, c-Rel, or RelB. For cold competition experiments, binding reactions contained a 50-fold molar excess of unlabeled competitor oligonucleotide. The positions of bands corresponding to binding of NF-&#x003ba;B p50 homodimers and p65/p50 as well as c-Rel/p50 and RelB/p50 heterodimers are indicated, as are &#x0201c;supershifted&#x0201d; complexes containing p50, p65, c-Rel, and RelB proteins (&#x02022;).</p></caption><graphic xlink:href="JEM981160.f2a"/><graphic xlink:href="JEM981160.f2b"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>T cell development in mI&#x003ba;B-&#x003b1; transgenic mice. Single cell suspensions of thymocytes from mI&#x003ba;B-&#x003b1; transgenic (Tg) and wild-type (WT) mice were stained with PE&#x02013;&#x003b1;-CD4 and FITC&#x02013;&#x003b1;-CD8 (A), or PE&#x02013;&#x003b1;-TCR-&#x003b1;/&#x003b2; and FITC&#x02013;&#x003b1;-CD3 (B) antibodies and analyzed by flow cytometry. Percentages of cells in the individual subpopulations are shown in the lower right quadrant. (C) Splenocytes from mI&#x003ba;B-&#x003b1; transgenic (Tg) and wild-type (WT) mice were stained with 7-amino actinomycin D, PE&#x02013;&#x003b1;-CD4, and FITC&#x02013;&#x003b1;-CD8, and were analyzed by flow cytometry. Total numbers (&#x000d7; 10<sup>6</sup> cells) of live CD4<sup>+</sup> and CD8<sup>+</sup> splenic T cells were determined from at least three mice in each group. The data is shown as mean &#x000b1; SD.</p></caption><graphic xlink:href="JEM981160.f3a"/><graphic xlink:href="JEM981160.f3b"/><graphic xlink:href="JEM981160.f3c"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Defective proliferation of mI&#x003ba;B-&#x003b1; thymocytes in response to mitogenic stimuli. Wild-type (WT) and mI&#x003ba;B-&#x003b1; transgenic (Tg) thymocytes were incubated with PMA (5 ng/ml) plus ionomycin (0.25 &#x003bc;g/ml; P + I), or stimulated with immobilized &#x003b1;-CD3 or &#x003b1;-CD3 plus &#x003b1;-CD28 antibodies (16 &#x003bc;g/ml) for 60 h at 37&#x000b0;C. Proliferation was measured by [<sup>3</sup>H]thymidine incorporation.</p></caption><graphic xlink:href="JEM981160.f4"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>Reduced cytokine production by mI&#x003ba;B-&#x003b1; transgenic thymocytes. Cultured thymocytes from wild-type (white bars) and transgenic I&#x003ba;B-&#x003b1;<sub>A32/36</sub> mice (black bars) were stimulated with immobilized &#x003b1;-CD3 plus &#x003b1;-CD28 antibodies (16 &#x003bc;g/ml). The levels of IL-2, GM-CSF, and IL-3 in the culture supernatants were assayed by ELISA 48 h after stimulation.</p></caption><graphic xlink:href="JEM981160.f5"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>Decreased &#x003b1;-CD3&#x02013;mediated deletion of DP thymocytes in mI&#x003ba;B-&#x003b1; transgenic mice. (A) 3&#x02013;7-wk-old wild-type (WT) or mI&#x003ba;B-&#x003b1; transgenic mice (Tg) were injected intraperitoneally with 200 &#x003bc;l of PBS containing either 0 (Control), 20, or 40 &#x003bc;g of &#x003b1;-CD3 mAb. Freshly isolated thymocytes from these animals were analyzed by flow cytometry with PE&#x02013;&#x003b1;-CD4 and FITC&#x02013;&#x003b1;-CD8 48 h after &#x003b1;-CD3 administration. (B) Absolute numbers of thymocytes in wild-type (<italic>n</italic> = 3) and mI&#x003ba;B-&#x003b1; transgenic (<italic>n</italic> = 4) animals 48 h after intraperitoneal injection with PBS or 40 &#x003bc;g of &#x003b1;-CD3 mAb. The data are shown as mean &#x000b1; SEM. (C) 3&#x02013;7-wk-old wild-type (WT) or mI&#x003ba;B-&#x003b1; transgenic mice (Tg) were treated with whole body &#x003b3; irradiation (500 RADs). Freshly isolated thymocytes from these animals were analyzed by flow cytometry with PE&#x02013;&#x003b1;-CD4 and FITC&#x02013;&#x003b1;-CD8 12 h after &#x003b3; irradiation.</p></caption><graphic xlink:href="JEM981160.f6b"/><graphic xlink:href="JEM981160.f6c"/><graphic xlink:href="JEM981160.f6a"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><p>Decreased &#x003b1;-CD3&#x02013;mediated thymocyte apoptosis in mI&#x003ba;B-&#x003b1; transgenic mice. Wild-type (WT) or mI&#x003ba;B-&#x003b1; transgenic (Tg) mice were injected intraperitoneally with 40 &#x003bc;g of &#x003b1;-CD3 mAb or an isotype-matched control antibody. Thymi were harvested and sections were analyzed for apoptotic lymphocytes by TUNEL assay. Each photomicrograph is representative of at least four different sections taken from each thymus. Original magnification: &#x000d7;400.</p></caption><graphic xlink:href="JEM981160.f7"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><p>Decreased &#x003b1;-CD3&#x02013;mediated deletion of DP thymocytes in FTOCs from mI&#x003ba;B-&#x003b1; transgenic mice. Thymi from embryonic day 17.5 wild-type (WT) or mI&#x003ba;B-&#x003b1; transgenic (Tg) mice were cultured for 72 h on semipermeable membranes in DMEM-10 plus 10% FCS in the absence (untreated) or presence of 10 &#x003bc;g/ml &#x003b1;-CD3 mAb (&#x003b1;-CD3). Thymocytes were analyzed by flow cytometry with PE&#x02013;&#x003b1;-CD4 and FITC&#x02013; &#x003b1;-CD8. Percentages of cells in the individual subpopulations are shown in the lower left quadrant.</p></caption><graphic xlink:href="JEM981160.f8"/></fig><fig id="F9" position="float"><label>Figure 9</label><caption><p>An NF-&#x003ba;B&#x02013;mediated pathway downregulates the expression of <italic>bcl-x<sub>L</sub></italic> after &#x003b1;-CD3 administration in vivo. (A) Expression of Bcl-2&#x02013;related genes in thymocytes after administration of &#x003b1;-CD3 mAb. Wild-type (WT) or mI&#x003ba;B-&#x003b1; transgenic mice (I&#x003ba;B-&#x003b1;<sub>A32/36</sub>) were injected intraperitoneally with 200 &#x003bc;l of PBS containing 0 (&#x02212;) or 40 &#x003bc;g of &#x003b1;-CD3 mAb and thymocyte RNA was prepared 24 or 48 h after treatment. Expression of Bcl-2&#x02013;related mRNAs was quantitated by RNAse protection assay. L32 is a control RNA that is present at equivalent levels in each of the samples assayed. Note the specific reduction in <italic>bcl-x<sub>L</sub></italic> mRNA levels in the WT thymocytes that was prevented in the mI&#x003ba;B-&#x003b1; thymocytes. (B) Western blot analysis of Bcl-x<sub>L</sub> expression in wild-type (WT) or mI&#x003ba;B-&#x003b1; (I&#x003ba;B-&#x003b1;<sub>A32/36</sub>) thymocytes from mice injected intraperitoneally with 40 &#x003bc;g of &#x003b1;-CD3 mAb for the times shown. Equivalent levels of expression of a slow mobility nonspecific control band demonstrate equal loading of the gel. (C and D) Expression of Bcl-x<sub>L</sub> in viable thymocytes from wild-type (WT) or mI&#x003ba;B-&#x003b1; (I&#x003ba;B-&#x003b1;<sub>A32/36</sub>) transgenic mice 24 h after intraperitoneal injection with 40 &#x003bc;g of &#x003b1;-CD3 mAb (dotted lines) or an isotype-matched control antibody (Control Ab; solid lines). Viable thymocytes (as determined by forward and side scatter gating) were analyzed by flow cytometry with Cy-Chrome&#x02013;&#x003b1;-CD4 and PE&#x02013;&#x003b1;-CD8 (see inserts for FACS<sup>&#x000ae;</sup> profiles). Thymocytes were fixed, permeabilized, and stained with an FITC&#x02013; &#x003b1;-Bcl-x<sub>L</sub> mAb. Levels of intracellular Bcl-x<sub>L</sub> in specific subpopulations of thymocytes were analyzed by gating on DP (C) and CD4<sup>+</sup> SP cells (D). Note the reduction in intracellular Bcl-x<sub>L</sub> levels seen in the wild-type DP thymocytes after &#x003b1;-CD3 treatment, which was observed neither in the mI&#x003ba;B-&#x003b1; DP thymocytes nor in the wild-type or mI&#x003ba;B-&#x003b1; SP thymocytes from these same animals.</p></caption><graphic xlink:href="JEM981160.f9a"/><graphic xlink:href="JEM981160.f9b"/><graphic xlink:href="JEM981160.f9c"/><graphic xlink:href="JEM981160.f9d"/></fig></floats-group></article>
